George H. Poste
CURRICULUM VITAE

Present Appointment:

George Poste, D.V.M., Ph.D, F.R.C. Path., F. Med Sci., CBE, F.R.S.
Director and Chief Scientist, Complex Adaptive Systems Initiative
Regents' Professor and Del E. Webb Chair in Health Innovation
Arizona State University
1475 N. Scottsdale Rd., Suite 361
Scottsdale, AZ 85257
Telephone: 480-727-8662
Fax: 480-884-2040
E-mail: george.poste@asu.edu
Website: https://casi.asu.edu/presentations/

Education, Qualifications and Honors:

1966	D.V.M.	University of Bristol, England (Veterinary Medicine) (Graduated first in class)
1966	M.R.C.V.S.	Member, Royal College of Veterinary Surgeons, London, England
1969	Ph.D.	University of Bristol, England (Virology)
1979	M.R.C. Path.	Membership, Royal College of Pathologists, London, England (Board Certification in Pathology)
1987	D.Sc.	University of Bristol, England. Distinguished Contributions to Research
1987	F.R.C.V.S.	Elected Fellow, Royal College of Veterinary Surgeons, London, England
1989	F.R.C. Path.	Elected Fellow, Royal College of Pathologists, London, England
1993	F.R.C.P. (Hon.)	Elected Fellow, Faculty of Pharmaceutical Medicine, Royal College of Physicians, London, England
1994	F.R.S.A.	Elected Fellow, Royal Society of Arts, Manufactures and Commerce, London, England
1995	LL.D. (Hon.)	University of Bristol, England
1997	F.R.S.	Elected Fellow, The Royal Society, London, England
1998	F.Med.Sci.	Elected Fellow, The Academy of Medical Sciences, London, England
1998	LL.D. (Hon.)	University of Dundee, Scotland
1999	C.B.E.	Commander of the Order of the British Empire, Honours List, H.M. Queen
1999	Honorary Fellow	University College London
2000	Member	Elected Member, Worshipful Company of Apothecaries, London
2004	Member	Council for Foreign Relations
2004	Award	Recipient of *Scientist of the Year* Award, R&D Magazine
2006	Award	Regents Professor, Arizona State University
2006	Award	Einstein Award, Global Business Leadership Forum
2009	Award	Pharmaceutical Industry Leadership Forum Scrip Lifetime Achievement Award
2016	Award	Arizona Bioindustry Association Lifetime Achievement Pioneer Award
2021	Member	Elected Fellow, American Institute for Medical and Biological Engineering (AIMBE)
2021	Member	Global Futures Scientist, Julie Ann Wrigley Global Futures Laboratory, Arizona State University

Previous Appointments:

2003 – 2009	Director, The Biodesign Institute, Arizona State University
2000 – 2003	Office of Secretary of Defense, Defense Science Board, Bioterrorism Task Force
2000 – 2003	Miscellaneous Board Responsibilities (see below)
1997 – 2000	Chief Science and Technology Officer, SmithKline Beecham, Philadelphia
1991 – 1997	President, Research and Development, SmithKline Beecham Pharmaceuticals, Philadelphia, PA
1989 – 1991	Executive Vice President, Research and Development, SmithKline Beecham Pharmaceuticals, Philadelphia, Pennsylvania
1988 – l989	President, Research and Development, SmithKline & French Laboratories, Philadelphia, Pennsylvania
1987 – 1988	Vice President, Worldwide Research and Preclinical Development, SmithKline & French Laboratories, Philadelphia, Pennsylvania
1983 – 1986	Vice President, Research and Development, SmithKline & French Laboratories, Philadelphia, Pennsylvania
1980 – 1983	Vice President, Director of Research, SmithKline & French Laboratories, Philadelphia, Pennsylvania
1975 – 1980	Principal Cancer Research Scientist, Department of Experimental Pathology, Roswell Park Memorial Institute, Buffalo, New York and Professor, Department of Cell and Molecular Biology, State University of New York at Buffalo
1974	Senior Lecturer, Department of Virology, Royal Postgraduate Medical School, University of London, England
1972 – 1974	Associate Professor of Experimental Pathology, Roswell Park Memorial Institute, Buffalo, New York (On official leave of absence from the University of London)
1970 – 1972	Lecturer in Virology, Royal Postgraduate Medical School, London, England
1969 – 1970	Research Fellow, Department of Virology, Royal Postgraduate Medical School, University of London, England
1966 – 1969	Research Fellow and Assistant Lecturer, Department of Bacteriology, University of Bristol, England

Board Memberships:

1992 – 2000	Board Member, SmithKline Beecham (retired on merger with Glaxo to create GlaxoSmithKline)
2000 – 2003	Board Member, Illumina
2000 – 2003	Board Member, Maxygen
1997 – 2003	Chairman, diaDexus (acquired by VaxGen)
2000 – 2003	Chairman, Structural GenomiX (acquired by Eli Lilly)
2002 – 2005	Board Member, AdvancePCS (acquired by CVS-Caremark)
2002 – 2009	Chairman, Orchid Biosciences (acquired by LabCorp.)
2003 – 2018	Board Member, Monsanto (acquired by Bayer)
2017 – 2025	Member, VirBiotech Scientific Advisory Board
2005 – 2026	Non-executive Vice Chairman, Caris Life Sciences
2015 – 2026	Chair, Scientific Advisory Board, A. Alfred Taubman Institute, University of Michigan
2008 – 2014	Haplogen Scientific Advisory Board
2009 – 2021	Scientific Advisory Board, Synthetic Genomics Inc.

Board Memberships Continued:

2004 – Present	Board Member, Exelixis
2016 – Present	Member, MIDAS External Advisory Board, University of Michigan
2026 – Present	Founding Member, International Society for Engineering Health (ISEH)

Professional and Civic Duties:

2025 – present	Chair of the Senior Science and Health Advisory Committee for the Observatory, ASU
1980 – 1983	Member, Scientific Advisory Panel, Biological Response Modifiers Program, National Cancer Institute
1983 – 1986	Member, Committee du Direction, Centre Nationale de Recherche Scientifique, (CNRS), Republic of France
1984 – 1986	Member, Board of Governors, National Association for Biomedical Research
1985 – 1989	Trustee, Gordon Research Conferences
1985 – 1990	Member, UCLA Conferences Symposium Board
1986 – 1995	Member, Board of Directors, The Royal Society of Medicine Foundation
1987 – 1989	Chairman, Research and Development Section, Pharmaceutical Manufacturers Association
1987 – 1992	Member, Board of Overseers of the School of Veterinary Medicine, University of Pennsylvania
1987 – 1993	Trustee, Philadelphia College of Pharmacy and Science
1988 – 1992	Member, Executive Council, International Society for Differentiation
1987 – 1993	Trustee, Philadelphia College of Pharmacy and Science
1988 – 1992	Member, Executive Council, International Society for Differentiation
1988 – 1992	Member, Scientific Advisory Board, Institute for Scientific Information, Philadelphia
1988 – 1992	Member, President's Council, M.D. Anderson Cancer Center, University of Texas
1989 – 1991	Member, Scientific Committee, Association of the British Pharmaceutical Industry (ABPI)
1992 – 1996	Trustee, The Keystone Center, Keystone, Colorado
1993 – 1997	Member, Board of Directors, Alliance for Aging Research
1993 – 1997	Member, Governor's Task Force on Economic Development, Commonwealth of Pennsylvania
1994 – 1997	Member, Research-Intensive Industries Task Force, Institute for the Future, Menlo Park, CA
1993 - 2003	Member, Governing Board, Beckman Center for Molecular and Genetic Medicine, Stanford University
1998 – 1999	Member, Advisory Committee on Global R&D, Council on Competitiveness, Washington, DC
1998 – 1999	Member, Standing Group on Health Technology, National Health Service (UK)
1998 – 1999	Member, National Health Service Executive Standing Group on Technology Assessment (UK)
1998 – 1999	Member, Ministerial Competitiveness Working Party on Innovation, Department of Trade and Industry (UK)
1997 – 1999	Member, Human Genetics Advisory Commission (UK)
1998 – 2000	Member, BP Technology Advisory Council
1998 – 2000	Member, Board of Medical Governors, World Economic Forum, Davos
1998 – 2001	Member, Rand Critical Technologies Task Force on the Hybrid Carbon Silicon Brain
1993 – 2003	Member, Governing Board, Beckman Center for Molecular and Genetic Medicine, Stanford University
2000 – 2009	Member, Defense Science Board, United States Department of Defense
2001 – 2005	Member, Threat Reduction Advisory Committee, United States Department of Defense
2003	Member, Journal and Editors Group: National Academy of Science and Center for Strategic and International Studies Panel “Scientific Publication and Security".
2003	Member, National Research Council Committee. Sharing Publication-Related Data and Materials:

Responsibilities of Authorship in the Life Sciences.

Professional and Civic Duties Continued:

2004	Member, Committee on Advances in Technology and the Prevention of their Application to Next Generation Biowarfare Agents. National Academy of Sciences
2005	Member, Committee International Perspective on Advancing Technologies and Strategies for Managing Dual-Use Risks. Institute of Medicine
2006	Member, Committee on Globalization, Biosecurity and the Future of the Life Sciences. Institute of Medicine
2008 – 2020	Member, National Academy of Medicine, Forum on Microbial Threats
2015	Member, Independent Assessment of the Health Care Delivery Systems and Management Processes of the Department of Veterans Affairs. September 1, 2015
2015-2025	Bipartisan Commission on Biodefense
Current	Member, Expert Advisory Group. Analysis of the Influenza Vaccine Enterprise and Recommendations for the Future. The University of Minnesota, the Center for Infectious Disease Research and Policy (CIDRAP).
Current	Member, Executive Committee, American Association for Cancer Research. Cancer Evolution Working Group
Current	Advisor, BiologyNext Initiative, In-Q-Tel, Inc.
Current	Member, Committee on a National Strategy for Cancer Control in the United States The National Academies of Sciences, Engineering, and Medicine (NASEM)
Current	Member, One Health Action Collaborative (OHAC) of the National Academies' Forum on Microbial Threats
Current	Member, National Biomarker Development Alliance (NBDA)

Editorial Responsibilities for Professional Publications:

1985 – 1996	Founder and Member, Editorial Board, Cancer and Metastasis Reviews
1987 – 1995	Member, Editorial Board, Cancer Invasion and Metastasis
1987 – 1999	Member, Editorial Board, Drug Targeting and Delivery
1988 – 1995	Member, Editorial Board, Clinical and Experimental Metastasis
1989 – 1999	Member, Editorial Board, International Journal of Pharmaceutics
1990 – 1998	Member, Editorial Board, Journal of Drug Targeting
1992 – 1999	Member, Editorial Board, Advanced Drug Delivery Reviews
Former	Member, Editorial Board, Nature Bio/Technology
Former	Member, Editorial Board, Current Opinion in Biotechnology
Former	Member, Editorial Board, Expert Opinion on Investigational Drugs
Former	Member, Senior Advisory Panel, Current Drugs
Former	Member, Editorial Board, Pharmacogenomics
Current	Member, Editorial Board, BioTechniques
Current	Member, Editorial Board, Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science
Current	Member, Editorial Board, Expert Opinion on Molecular Diagnostics
Current	Member, Editorial Board, Health Security

Club Memberships:

Current	Athenaeum, London
Current	Paradise Valley Country Club, Arizona

Published Works:

1. J Abraham, V Domenyuk, N Perdigones, S Klimov, S Antani, T Yoshino, ...(2025) Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors Scientific reports 15 (1), 21173 https://doi.org/10.1038/s41598-025-08986-0
2. Poste, G., F Lentzos, B Johnson, DR Gillum (2025) Introduction to Biosafety and Biosecurity for Potential Pandemic Pathogens and Dual-Use Research of Concern. 30 (2), 67-68 https://doi.org/10.1089/apb.2025.0019
3. Poste, G., Lentzos, F., Johnson, B. and Gillum, D. R. (2025) Editors. Special Issue: Biosafety and Biosecurity for Potential Pandemic Pathogens and Dual-Use Research of Concern. Applied Biosafety. 30, (2), 67 https://doi.org/10.1089/apb.2025.0019
4. J Abraham, V Domenyuk, M Perdigones Borderias, S Klimov, S Antani, Poste, G. (2025) AI enabled exome and transcriptome liquid biopsy platform spanning the continuum of care in oncology medRxiv, DOI: 10.1101/2025.05.23.25328255v1
5. Abraham, J., Domenyuk, V., Perdigones, N. *et al.* (2025). Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors. *Sci Rep* **15**, 21173 https://doi.org/10.1038/s41598-025-08986-0
6. Nickerson CA, McLean RJC, Barrila J, Yang J, Thornhill SG, Banken LL, Porterfield DM, Poste G, Pellis NR, Ott CM. (2024) Microbiology of human spaceflight: microbial responses to mechanical forces that impact health and habitat sustainability. Microbiol Mol Biol Rev. doi: 10.1128/mmbr.00144-23. Epub ahead of print. PMID: 39158275.
7. Ex Officio Member: Bipartisan Commission on Biodefense. (2024). The National Blueprint for Biodefense - Immediate Action Needed to Defend Against Biological Threats. https://biodefensecommission.org/reports/the-national-blueprint-for-biodefense/
8. Ex Officio Member: Bipartisan Commission on Biodefense. (2024). Box The Pox. Reducing The Risk of Smallpox and Other Orthopoxviruses. https://biodefensecommission.org/wp-content/uploads/2024/02/2024.02.20-Box-the-Pox.pdf
9. Inglesby, T. et al. (2023). Response to OSTP RFI on Policies for Oversight of DURC and P3CO Framework. https://centerforhealthsecurity.org/sites/default/files/2023-10/v2-2023-10-16-rfi-durc-p3co.pdf
10. Poste, G., & Gillum, D. (2023). Biotech promises miracles. But the risks call for more oversight. https://thebulletin-org.cdn.ampproject.org/c/s/thebulletin.org/2023/08/biotech-promises-miracles-but-the-risks-call-for-more-oversight/amp/
11. Poste, G., & Gillum, D. (2023). Researchers hacked a lab's pathogen containment system. Was it a good idea to publish the results? https://thebulletin.org/2023/01/researchers-hacked-a-labs-pathogen-containment-system-was-it-a-good-idea-to-publish-the-results/#post-heading
12. Nickerson CA, Medina-Colorado AA, Barrila J, Poste G, Ott CM. (2022) A vision for spaceflight microbiology to enable human health and habitat sustainability. Nat Microbiol. (4):471-474. Doi: 10.1038/s41564-021-01015-6.
13. Johns Hopkins Center for Health Security. (2022). Recommendations to Strengthen the US Government's Enhanced Potential Pandemic Pathogen Framework and Dual Use Research of Concern Policies. https://centerforhealthsecurity.org/sites/default/files/2023-02/220629-recstostrengthenusgepppanddurcpolicies.pdf
14. Ex Officio Member: Bipartisan Commission on Biodefense. (2022). Boots on the Ground: Land-Grant Universities in the Fight Against Threats to Food and Agriculture. Washington, DC: Bipartisan Commission on Biodefense https://biodefensecommission.org/reports/boots-on-the-ground-land-grant-universities-in-the-fight-against-threats-to-food-and-agriculture/
15. Ott, CM, et al., (2021). Vision for the Next Generation of Spaceflight Microbiology: Human Health and Habitat Sustainability. Decadal Survey on Biological and Physical Sciences Research in Space 2023-2032 conducted by the National Academies of Science, Engineering and Medicine. Washington D.C.
16. Lennerz, J.K., Marble, H.D., Lasiter, L. et al. (2021). Do not sell regulatory science short. Nat. Med. https://doi.org/10.1038/s41591-021-01298-6
17. Ex Officio Member: Bipartisan Commission on Biodefense. (2021). Saving Sisyphus: Advanced Biodetection for the 21st Century. Washington, DC: Bipartisan Commission on Biodefense. https://biodefensecommission.org/reports/saving-sisyphus-advanced-biodetection-for-the-21st-century/
18. Bipartisan Commission on Biodefense. (2021). Insidious Scourge: Critical Infrastructure at Biological Risk. Bipartisan Commission on Biodefense: Washington, DC. https://biodefensecommission.org/reports/insidious-scourge-critical-infrastructure-at-biological-risk/
19. Ex Officio Member: Bipartisan Commission on Biodefense. Biodefense in Crisis: Immediate Action Required to Address National Vulnerabilities. (2021). https://biodefensecommission.org/reports/biodefense-in-crisis-immediate-action-needed-to-address-national-vulnerabilities/
20. Ex Officio Member: The Apollo Program for Biodefense. Winning the Race Against Biological Threats. Bipartisan Commission Report. (2021) https://biodefensecommission.org/reports/the-apollo-program-for-biodefense-winning-the-race-against-biological-threats/
21. Moses, H., III and Poste, G. "Reducing Systemic Vulnerabilities in US Health Care." National Academy of Engineering: Winter

Issue of The Bridge on Complex Unifiable Systems. (2020) 50, (4) 50-52., http://www.nae.edu/244717/Reducing-Systemic-Vulnerabilities-in-US-Health-Care.

22. Madhavan, G., Poste, G. and Rouse, W. Editors. Complex Unifiable Systems., National Academy of Engineering: The Bridge. vol. 50, (4) https://www.nae.edu/244665/Winter-Issue-of-The-Bridge-on-Complex-Unifiable-Systems
23. Panel Member. Bipartisan Commission on Biodefense. Diagnostics for Biodefense - Flying Blind with No Plan to Land (2020) https://biodefensecommission.org/reports/diagnostics-for-biodefense-flying-blind-with-no-plan-to-land/

    https://www.newamerica.org/weekly/six-steps-to-fix-our-public-health-agencies-testing-capabilities-in-the-pandemic/
24. Poste. G. (2020). Six Steps to Fix Our Public Health Agencies' Testing Capabilities in the Pandemic. New America, https://www.newamerica.org/weekly/six-steps-to-fix-our-public-health-agencies-testing-capabilities-in-the-pandemic/
25. Poste. G. (2020). Isaiah J. (Josh) Fidler, DVM, PhD, FAACR: In Memoriam (1936-2020)- A Visionary Research Career Dedicated to Understanding the Complexities of Cancer Metastasis. Cancer Research. DOI:10.1158/0008-5472.CAN-20-1905 https://cancerres.aacrjournals.org/content/80/15/3059
26. Committee Member (2020). A Strategy for the Future of the International Space Station (ISS) National Laboratory (ISSNL) and Commercial Low-Earth Orbit (LEO) Development. National Aeronautics and Space Administration. https://www.nasa.gov/wp-content/uploads/2023/09/iss-cooperative-agreement-irt-final-report.pdf
27. Moses, H., III, Matheson, D.H.M. and Poste, G. (2019) "Serving Individuals and Populations Within Integrated Health Systems. A Bridge Too Far?" JAMA, 321, 1975, doi:10.1001/jama.2019.2929 https://pubmed.ncbi.nlm.nih.gov/30920581/
28. National Academies of Sciences, Engineering, and Medicine. (2019). Guiding Cancer Control: A Path to Transformation. Washington, DC: The National Academies Press. https://doi.org/10.17226/25438
29. Panel Member, Blue Ribbon Panel on Biodefense. Holding the Line on Biodefense. State, Local, Tribal, and Territorial Reinforcements Needed A Bipartisan Report of the Blue Ribbon Study Panel on Biodefense (2018). https://www.biodefensestudy.org/Holding-the-Line-on Biodefense
30. Panel Member, Blue Ribbon Study Panel on Biodefense. Budget Reform for Biodefense: Integrated Budget Needed to Increase Return on Investment (2018). https://biodefensecommission.org/reports/budget-reform-for-biodefense/
31. Togami, E., J. L. Gardy, G. R. Hansen, G. H. Poste, D. M. Rizzo, M. E. Wilson, and J. A. K. Mazet. (2018). Core Competencies in One Health Education: What Are We Missing? NAM Perspectives. Discussion Paper, National Academy of Medicine Perspectives, Washington, DC. https://nam.edu/core-competencies-in-one-health-education-what-are-we- missing
32. Domenyuk, V., Gatalica, Z., Santhanam, R., Wei, X., Stark, A. Kennedy, P., Toussaint, B., Levenberg, S., Wang, J., Nianqing, X., Greil, R., Rinnerthaler, G., Gampenrieder, S., Heimberger, A., Berry, D., Barker, A., Quackenbush, J., Marshall, J., Poste, G., Vacirca, J., Vidal, G., Schwartzberg, L., Halbert, D., Voss, A., Magee, D., Miglarese, M., Famulok, M., Mayer, G., and Spetzler, D. "Poly-Ligand Profiling Differentiates Trastuzumab-Treated Breast Cancer Patients According to their Outcomes" Nature Communications (2018) https://www.nature.com/articles/s41467-018-03631-z
33. Panel Member. Bipartisan Commission on Biodefense. Diagnostics for Biodefense Defense of Animal Agriculture (2017) https://biodefensecommission.org/reports/defense-of-animal-agriculture/
34. MacIntyre, C. R., Engells, T. E., Scotch, M., Heslop, D. J., Gumel, A. B., Poste, G., Chen. X., Herche, W., Steinhöfel, K., Lim, S., and Broom, A. "Converging and Emerging Threats to Health Security" Environment System Decisions, (2017). https://doi.org/10.1007/s10669-017-9667-0
35. Alexander, B. M., Ba, S., Berger, M. S., Berry, D. A., Cavenee, W. K., Chang, S. M., Cloughesy, T. F., Jiang, T., Khasraw, M., Li, W., Mittman, R., Poste, G. H., Wen, P. Y., Yung, W. K. A., and Barker, A. D. "Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE" Clinical Cancer Research 24(3) (2017) DOI: 10.1158/1078-0432.CCR-17-0764 https://clincancerres.aacrjournals.org/content/clincanres/24/4/737.full.pdf
36. Poste, G. (2017). "The Complex Strategic Landscape for Precision Medicine: Cost, Convergence, Culture, Computing and Creative Destruction" Journal of Precision Medicine, 3, 36-51. https://www.dropbox.com/scl/fi/upp63nen7o63085zn575e/G.-Poste-The-Complex-Strategic-Landscape-for-Precision-Medicine-2017-Journal-of-Prec-Medicine.pdf?rlkey=pg3s2ozohf2gvuuhkjhujre5t&dl=0
37. Domenyuk, V., Zhong, Z., Stark, A., Xiao, N., O'Neill, H. A.Wei, X., Wang, J., Tinder, T. T., Tonapi, S., Duncan, J., Hornung, T., Hunter, A., Miglarese, M. R., Schorr, J., Halbert, D. D., Quackenbush, J., Poste, G., Berry, D. A., Mayer, G., Famulok, M., and Spetzler, D. (2017) "Plasma Exosome Profiling of Cancer Patients by a Next Generation Systems Biology Approach" Nature Scientific Reports | 7:42741 | DOI: 10.1038/srep42741

    DOI: 10.1080/2162402X.2016.1145332
38. D.A., Okada, H., and Heimberger, A.B. "Prioritization Schema for Immunotherapy Clinical Trials in Glioblastoma." OncoImmunology 5, 6 (2016)
39. Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF, Berger MS, Poste GH, Khasraw M, Ba S, Jiang T, Mikkelson T, Yung WK, de Groot JF, Fine H, Cantley LC, Mellinghoff IK, Mitchell DA, Okada H, Heimberger AB. Prioritization

schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology. 2016 Feb 18;5(6):e1145332. doi: 10.1080/2162402X.2016.1145332. PMID: 27471611; PMCID: PMC4938323.

40. Panel Member (2015) Bipartisan Report of the Blue Ribbon Panel on Biodefense (https://biodefensecommission.org/reports)
41. Member, Veterans Choice Act, Blue Ribbon Panel. "Independent Assessment of the Health Care Delivery Systems and Management Processes of the Department of Veterans Affairs. Veterans Access, Choice, and Accountability Act of 2014" Section 201. Prepared by the Department of Veterans Affairs. A Product of the CMS Alliance to Modernize Healthcare Federally Funded Research and Development Center, (2015). Print. Volume I: Integrated Report. Task Order No. VA118A14F0373-384.
42. Osterholm, M., Moore, K., Ostrowsky, J., Kimball-Baker, K., Farrar, J., and Wellcome Trust-CIDRAP Ebola Vaccine Team B (Poste, G.). (2015) The Ebola Vaccine Team B: a model for promoting the rapid development of medical countermeasures for emerging infectious disease threats. Lancet Infectious Diseases 16(1). (2015) (DOI:
43. Castillo-Chavez C, Curtiss R, Daszak P, Levin SA, Patterson-Lomba O, Perrings C, Poste G, Towers S. Beyond Ebola: lessons to mitigate future pandemics. Lancet Glob Health. 2015 Jul;3(7):e354-5. doi: 10.1016/S2214-109X(15)00068-6. PMID: 26087978; PMCID: PMC7128928.
44. Member, International Ebola Vaccine Team Report. (2015) "Recommendations for Accelerating the Development of Ebola Vaccines: Report & Analysis" http://www.cidrap.umn.edu/sites/default/files/public/downloads/ebola_virus_team_b_report- final-021615.pdf
45. Poste, G. (n.d.). Precision oncology: Big data and analytics come to cancer care. Precision Oncology Big Data And Analytics Come To Cancer Care. https://www.lifescienceleader.com/doc/precision-oncology-big-data-and-analytics-come-to-cancer-care-0001
46. Barker A., Compton C., Poste G. (2014) The National Biomarker Development Alliance (NBDA): Accelerating the Translation of Biomarkers to the Clinic. Biomarkers Med. 8(6), 873-876 http://www.futuremedicine.com/doi/pdf/10.2217/bmm.14.52
47. Poste G., Barker A., Compton C. (2014) The National Biomarker Development Alliance (NBDA): Confronting the Poor Productivity of Biomarker Research and Development. Expert Rev. Mol. Diagn. (doi:10.1586/14737159.2015.974561)
48. R. Juliano, G. Poste, E. Tomlinson. (2013) Perspective from the founding editors. Advanced Drug Delivery Reviews. Volume 65, Issue 1., Pg. 3-4 https://doi.org/10.1016/j.addr.2012.07.017Get rights and content
49. Interview George Poste: One step ahead (2013) Bulletin of the Atomic Scientists 69, 6, 1-10 https://thebulletin.org/2013/11/george-poste-one-step-ahead/
50. Lindor, R.A., Allocco, S.J., Cheatham, L., Cortese, D.A., Hall, F.H., Mangold Jr., W.J., Pizziconi, V., Poste, G., Quinn, B., Roth, M., Saks, M.J., Wassman, E.R., Woosley, R.L., and Marchant, G. (2013) Regulatory and Reimbursement Innovation for Molecular Diagnostics: Parallel Review and Coverage with Evidence Development. Sci Transl Med. 5, 176, p. 176cm3. DOI:10.1126/scitranslmed.3005437
51. Poste, G. (2012) Biospecimens, biomarkers, and burgeoning data: the imperative for more rigorous research standards. Trends in Molecular Medicine. 18, pp. 717-722 https://doi.org/10.1016/j.molmed.2012.09.003
52. Adalja A.A., Wollner S. B., Inglesby T.V., Poste, G. (2012) The Globalization of US Medical Countermeasure Production and Its Implications for National Security. Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science. 10(3): 255-257.
53. Poste, G. (2012) Member, Kauffman Task Force on Cost-Effective Health Care Innovation. Report "Valuing Health Care: Improving Productivity and Quality" https://www.kauffman.org/wp-content/uploads/2012/04/valuing_health_care.pdf
54. Poste, G., Carbone, D.P., Parkinson, D.R., Verweji, J., Hewitt, S.M., Jessup, J.M. (2012) Leveling the Playing Field: Bringing Development of Biomarkers and Molecular Diagnostics up to the Standards for Drug Development. Clin. Cancer Res. 18:1515-1523. DOI: 10.1158/1078-0432.CCR-11-2206
55. Poste, G. (2011) US Patent No. 7888035, Klass et al., Date of Patent Feb. 15, 2011
56. Poste, G. (2011) Bring on the biomarkers. Nature. 469, 156-157 https://pubmed.ncbi.nlm.nih.gov/21228852/
57. Poste. G. (2009) Panel Member, The Institute of Medicine's (IOM's) Forum on Infectious Diseases, The Domestic and International Impacts of the 2009-H1N1 Influenza A Pandemic: Global Challenges, Global Solutions. Workshop Summary National Academies Press. ISBN-13: 978-0-309-14677
58. Poste, G. (2009) What's in a name? Nature Biotechnology. 27, 1071-1073
59. Claudia Acquisti, George Poste, David Curtiss, Sudhir Kumar (2007) Nullomers: Really a Matter of Natural Selection? PLoS ONE. 2(10): e1022. doi:10.1371/journal.pone.0001022
60. Poste, G. (2006) Animal Testing a Necessary Research Tool, For Now. Arizona Republic, September 3, 2006.
61. Poste, G (2005) Incorporating appropriate technology into North American schools of public health, Pan Am JPublic Health 19(2), 2005
62. Poste, G. (2005) Issues in Bioterrorism and Defense: A View of the Future in Technology Futures and Global Power, Wealth and Conflict. Ed. A.K. Solomon. Center for Strategic and International Studies (CSIS), Washington, DC.

63. Committee Member, (2006) Institute of Medicine and National Research Council Report: Globalization, Biosecurity and the Future of the Life Sciences. Washington, DC https://nap.nationalacademies.org/resource/11567/pga_054636.pdf

64. Committee Member, (2005) Institute of Medicine and National Research Council Report. An International Perspective on Advancing Technologies and Strategies for Managing Dual-Use Risks. National Academy Press, Washington, DC. https://nap.nationalacademies.org/read/11301/chapter/1
65. Poste, G (2003) Genes and Molecular Medicine Proceedings of Cambridge Symposium to Celebrate 50 Years of the Double Helix. MRC Laboratory of Molecular Biology, Cambridge. Pp 16-21.
66. Bootman, J.L., Eichler, H-G., Jonsson, B., Moerman, D. and Poste, G. (2003). Achieving the value of medicines. International Forum on Medicines - International Pharmaceutical Federation, The Hague, The Netherlands.
67. Eichler, H-G., Bootman, J.L., Jonsson, B., Moerman, D., and Poste, G. (2003). The need to assess the value of medicines. International Forum on Medicines - International Pharmaceutical Federation, The Hague, The Netherlands.
68. Bootman, J.L., Eichler, H-G, Jonsson, B., Moerman, D., Poste, G., Kielgast, P., Hock, T. and Sousa-Pinto, G. (2003). An agenda for health priorities. International Forum on Medicines - International Pharmaceutical Foundation, The Hague, The Netherlands.
69. Member, Journal and Editors Group: National Academy of Science and Center for Strategic and International Studies Panel (2003) "Statement on Scientific Publication and Security". Proc. Nat. Acad. Sci. USA 100, 464 and Nature 421, 771.
70. Committee Member, (2003) National Research Council. Sharing Publication-Related Data and Materials: Responsibilities of Authorship in the Life Sciences. Washington, DC: The National Academies Press,
71. Poste, G. (2002) Biotechnology, Bioterrorism and Biosecurity. Drug Discovery World. Summer 2002, pp. 9-21.
72. Poste, G. (2002) Facing Reality in Preparing for Biological Warfare. Health Affairs 21.
73. Poste, G. (2002) Biotechnology and Terrorism. Prospect. #74, 48-52.
74. A Rude Awakening to the Forces of Good and Evil. Financial Times Biotechnology Survey. 27 November 2001.
75. The Dawning Life Sciences Defense Industry. An Interview with George Poste. In Vivo 2001 19 (9) 1-9.
76. Poste, G. (2001) Molecular diagnostics: a powerful new component of the healthcare value chain. Expert Rev. Mol. Diag. 1, 1-5.
77. Poste, G (2001) Genomics at the Cutting Edge. Financial Times 26 September 2001.
78. Poste, G. (2000) Biotechnology and the Evolution of Molecular Medicine. J. Biolaw Supplement 2000, 12-16.
79. Poste, G. (2000) The Nation is Falling Apart. Financial Times 4 December 2000
80. Poste, G. (2000) R&D in the Post-Genome World: The Challenge of Systems Biology, Financial Times Biotechnology Survey 16 November 2000.

81. Poste, G. (2000) Revealing Reality Within a Body of Imaginary Things. Essays for Theories, Models, Methods, Approaches, Assumptions and Findings". Catalog for Damien Hirst Exhibition, Gagosian Gallery, New York, September 2000
82. Fears, R., Roberts, D. Poste, G. (2000) Rational or rationed medicine? The promise of genetics for improved clinical practice. BMJ, April 2000, pp. 933-935.
83. Poste, G. (2000) The First battleground for the regulation of e.commerce. Financial Times 6 April 2000, Life Sciences Supplement IV.
84. Poste, G. (2000) The right treatment, for the right disease, for the right patient. Scrip Magazine, January, Issue 86.
85. Poste, G. (1999) The new risks to scientific progress, Financial Times, Life Sciences Supplement, 28 October, p. VII.
86. Poste, G., Bell, J., Davies, K., Goodfellow, P. and Hastie, N. (1999) Editors. Impact of genomics on healthcare. British Medical Bulletin, 55 (2), Royal Society of Medicine Press, London, 496 pp.
87. Fears, R., Weatherall D. and Poste, G. (1999) The impact of genetics on medical education and training. British Medical Bulletin, 55 (2), pp. 460-70.
88. Fears, R. and Poste, G. (1999) SmithKline Beecham and the future direction of medical research. Science in Parliament, Summer Issue, 56 (3), 10-11.
89. Poste, G. and Fears, R. (1999) The best ways forward. Science & Public Affairs, Special Issue, June, pp. 4-5.
90. Poste, G. (1999) Making more of yourself. Financial Times, Life Sciences Supplement, 15 July, p. 6.
91. Poste, G. and Fears, R. (1999) How to maximise the benefits of molecular medicine: integrated system to promote progress. UK Houses of Parliament, Biotechnology Supplement, May 3, pp. 12-3.
92. Poste, G. (1999) Not invented here: the old bromide has run its course, probably forever. The Genesis Report/Rx, February 8(2), 8-9.
93. Fears, R. and Poste, G. (1999) Building population genetics resources using the U.K. NHS. Science, 284, 267-68.

94. Poste, G. (1999) Antibiotic armageddon. Financial Times, Post Script, March 15, p. 6.
95. Ruffolo, Jr., R.R., Feuerstein, G.Z., Hunter, A.J., Poste and G. Metcalf, B.W. (1999) Inflammatory cells and mediators in CNS diseases. New Horizons in Therapeutics, Harwood Academic Publishers, The Netherlands.
96. Poste, G. and Fears, R. (1999) Joining up for the genome. Times Higher, Educational Supplement 19, February, pp. 40-1.
97. Fears, R. and Poste, G. (1998) British science policy: reasons to be cheerful and careful. Science and Public Affairs, The British Association, Winter Issue.
98. Poste, G. (1998) Science, Innovation and the Evolution of Genetic Medicine. European BioPharmaceutical Review, December, pp. 62-8.
99. Feuerstein, G.Z., Poste, G., Shusterman, N.H. and Ruffolo, Jr., R.R. (1998) The changing paradigm for pharmacotherapy of congestive heart failure. International Journal of Cardiovascular Medicine and Science, 1, 171-89.
100. Poste, G. (1998) Molecular medicine and information-based targeted healthcare. Nature Biotechnology, 16 (Supplement), 19-21. https://doi.org/10.1038/5403
101. Poste, G. (1998) New frontiers, new hurdles. The Parliament Magazine, May 4, p. 12.
102. Poste, G. (1998) Hard choices must be made for a competitive future. Research Fortnight, February 11, p. 13.
103. Yue, T-L, Ma, X-L, Wang, X., Romanic, A.M., Liu, G-L, Louden, C., Gu, J-L, Kumar, S., Poste, G.Ruffolo, Jr. and R.R. Feuerstein, G.Z. (1997) Possible involvement of stress-activated protein kinase signaling pathway and fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circulation Research, 82, 166-74.
104. Ruffolo, Jr., R.R., Poste, G. and Metcalf, B. (1997) Editors. Cell cycle regulation. New Horizons in Therapeutics, Harwood Academic Publishers, The Netherlands.
105. Poste, G. (1997) "Science, Medicine and Society: Progress, Perils, Opportunities and Opponents. (George Poste, Chief Science and Technology Officer, President, Research and Development Pharmaceuticals, SmithKline Beecham, Commencement Address University of Cambridge, Cambridge, England, Jun 28, 1997)." Vital Speeches of the Day, vol. 63, no. 24, 1997, p. 755
106. Poste, G. (1997) In praise of excellence. Financial Times, Invited Editorial, August 1, p. 16.
107. Poste, G., Roberts, D. and Gentry, S. (1997) Patents, ethics and improving healthcare. Bulletin of Medical Ethics, 124, 29-31.
108. Fears R, Ferguson MW, Stewart W, Poste G. Life-sciences R&D, national prosperity, and industrial competitiveness. Science. 1997 May 2;276(5313):759-60. doi: 10.1126/science.276.5313.759. PMID: 9157555.
109. Poste, G. (1997) Looking back to the future: healthcare by 2022. Scrip Magazine, April, p. 34-7.
110. Poste, G. (1997) Managing discontinuities in healthcare markets and technology. Vital Speeches of the Day, LXIII (10), 309-13.
111. Chopra, I., Hodgson, J., Metcalf, B. and Poste, G. (1997) The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics. Antimicrobial Agents and Chemotherapy, 41, 497-503.
112. Poste, G. (1997) The science of the possible. Times Higher, February, p. 12.
113. Poste, G. (1997) Fight for your future. Pharmaceutical Times, January, p. 40.
114. Greller, L.D., Tobin, F.L. and Poste, G. (1996) Tumor heterogeneity and progression: conceptual foundations for modeling. Invasion & Metastasis, 16, 177-208.
115. Feuerstein, G.Z., Shusterman, N.H., Poste, G., Ruffolo, Jr., R.R. (1996) Beta-blockers and heart failure rationale and highlights and highlights from the carvedilol heart failure trials. Pharmaceutical News, 3, 18-23.
116. Poste, G. (1996) A strategy to promote a national asset. Financial Times, Invited Editorial, July 19, p. 12.
117. Poste, G. (1996) An acid test for excellence. Financial Times, Invited Editorial, June 7, p. 16.
118. Fears, R. and Poste, G. (1996) Challenges in R&D. Science and Parliamentary Affairs, Summer Issue, pp. 5-6.
119. Poste, G. (1996) Is SmithKline's future in its genes? Business Week, March 4, pp. 80-1.
120. Chopra, I., Hodgson, J. Metcalf, B., and. Poste, G., (1996) New approaches to the control of infections caused by antibiotic- resistant bacteria. Journal of the American Medical Association, 275, 401-03.
121. Poste, G. and McCormick D. (1995) Genomics: history and science in the making. The Biotechnology Report, (ed. H. Price), pp. 68-9. Campden Publishing Limited, London.
122. Greller, L.D., Tobin, F.L. and Poste, G. (1995) Computational tumor heterogeneity and progression. Computational Medicine, Public Health, and Biotechnology (Part 1). (ed. M. Witten), 5, pp. 413-41. World Scientific Publishing Company, New Jersey.
123. interactions in tumor dynamics. International Workshop on Information Processing in Cells and Tissues, pp. 569-73. The University of Liverpool, England.
124. Greller, L.D., Tobin, F.L., Poste, G. and Wang, X. (1995) Genetic instability and progression
125. Fears, R and Poste G. (1995) Enabling the future: an industry perspective on the foresight science policy exercise in the life sciences. Science Technology and Innovation,8, 26-30.

126. Poste, G. (1995) The case for genomic patenting. Nature, 378, 534-6.

127. Poste, G. (1995) There was a false comfort in healthcare. Pharmaceutical Times, October, 28-34.

128. Warner, M. and Poste, G. (1995) Editors. The impact of the new genetics on the NHS. The Cardiff Debate, Welsh Health Planning Forum, Cardiff, Wales.

129. Feuerstein, G.Z., Poste, G. and Ruffolo, Jr., R.R. (1995) Carvedilol update III: rationale for use in congestive heart failure. Drugs of Today, 31, 307-26.

130. Poste, G. (1995) Science: The view from industry. Times Higher, Education Supplement, April 21, 1995, p. 11.

131. Poste, G. (1995) The study of genes and their functional regulation. Vital Speeches of the Day, LXI (6), 165-69.

132. Gregoriadis, G., McCornack, B., Poste, G. (1994) Editors. Targeting of Drugs. Advances in system constructs. NATO ASI Series. Series A: Life Sciences, Vol. 273, Plenum Press, New York.

133. Ohlstein, E.H., Nambi, P., Douglas, S.A., Edwards, R.M., Gellai, M., Lago, A., Leber, J.D., Cousins, R.D., Gao, A., Frazee, J.S., Peishoff, C.E., Bean, J.W., Eggleston, D.S., Elshourbagy, N.A., Kumar, C., Lee, J.A., Yue, T-L., Louden, C., Brooks, D.P., Weinstock, J., Feuerstein, G., Poste, G., Ruffolo, Jr., R.R., Gleason, J.G., Elliott, J.D. (1994) SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist. Proceedings of the National Academy of Sciences, 91, 8052- 8056.

134. Ruffolo, Jr., R.R. and Poste, G. (1994) A prescription for better prescriptions: a response. Issues in Science and Technology, Summer Supplement, p. 9.

135. Poste, G. (1994) This house believes the NHS can no longer afford the best medicines. The Great Oxford Debate. Pharmaceutical Times, November, pp. 26-29.

136. Poste, G. and Fears, R. (1994) Industry's crystal ball. Science & Public Affairs, Autumn, pp. 4-6.

137. Fears, R., Greig, R., Poste, G. (1994) Human genomic research and innovative medicine. Science in Parliament, 51, 4-5.

138. Poste, G. (1994) R&D strategies in the pharmaceutical industry. R&D Efficiency, 3, 1-8.

139. Fears, R. and Poste, G. (1994) Obstacles to the development of novel thrombolytic agents for acute myocardial infarction therapy: is the good the enemy of the best? Fibrinolysis, 8, 214-20.

140. Fan, D., Poste, G., Seid, C., Earnest, L., Bull, T., Clyne, R., and Fidler, I. (1994) Reversal of multidrug resistance in murine fibrosarcoma cells by thioxanthene flupentixol. Investigational New Drugs, 12, 185-95.

141. Fears, R., Suckling K. and Poste, G. (1994) Novel agents in the treatment of atherosclerosis. Exp. Opin. Invest. Drugs, 3, 481-91.

142. Metcalf, B., Dalton, B.J., Poste, G. (1994) Editors. Cellular adhesion: molecular definition to therapeutic potential. New Horizons in Therapeutics, Plenum Press, New York.

143. -adrenoceptor antagonist furobenzazepine. International Journal of Oncology, 4, 789-98.

144. I.J. (1994) Circumvention of multidrug resistance in murine fibrosarcoma and colon carcinoma cells by treatment with the

145. Fan, D., Poste, G., Ruffolo, Jr., R.R., Dong, Z., Seid, C., Earnest, L.E., Campbell, T.E., Clyne, R.K., Belltran, P.J., Fidler,

146. Gregoriadis, G., McCormack, B., Allison, A.C., Poste, G. (1993) Editors. New generation vaccines. The role of basic immunology. NATO ASI Series. Series A: Life Sciences. Vol 261. Plenum Press, New York.

147. Poste, G., (1993) Defining a strategy for healthcare research & development in turbulent times. Pharmaceutical Forum, Issue 2, pp. 11-15. Amersham International plc, Little Chalfont (UK).

148. Poste, G., (1993) Genetics, economics and ethics: the new trinity shaping the future direction of healthcare. Campaign for Resource. pp. 1-8, University of Bristol, London, England.

149. Smith, R.A.G., Dewdney, J.M., Fears, R., and Poste, G. (1993) Chemical derivatization of therapeutic proteins. Trends in Biotechnology, 11(9), pp. 397-403. Elsevier Science Publishers Ltd. (UK).

150. Ohlstein, E.H., Douglas, S.A., Sung, C.P., Yue, T.L., Louden, C., Arleth, A., Poste, G., Ruffolo, Jr., R.R., Feuerstein, G.Z. (1993) Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration and neointimal formation following vascular injury. Proceedings of the National Academy of Sciences, Vol. 90, pp. 6189-93.

151. Fan, D., Poste, G., O'Brian, C.A., Seid, C., Ward, N.E., Earnest, L.E., Fidler, I.J. (1992) Chemosensitization of murine fibrosarcoma cells to drugs affected by the multidrug resistance phenotype by the antidepressant trazodone: an experimental model for the reversal of intrinsic drug resistance. International Journal of Oncology, 1, 734-42. National Hellenic Research Foundation, Athens, Greece.

152. Nichols, A.J., Ruffolo, Jr., R.R., Huffman, W.F., Poste, G. and Samanen, J. (1992) Development of GPIIb/IIIa antagonists as antithrombotic drugs. Trends in Pharmacological Sciences, Vol. 13, pp. 413-17. Elsevier Science Publishers Ltd. (UK).

153. Ruffolo, Jr., R.R., Boyle, D.A., Brooks, D.P., Feuerstein, G.Z., Venuti, R.P., Lukas, M.A., Poste, G. (1992) Carvedilol: a novel cardiovascular drug with multiple actions. Cardiovascular Drug Reviews, Vol. 10, No. 2, pp. 127-57. Neva Press, Inc.

154. Gregoriadis, G., Florence, A.T., Poste, G. (1991) Editors. Targeting of drugs 3: the challenges of peptides and proteins. NATO ASI Series. Series A: Life Sciences. Vol 238. Plenum Press, New York. Conference Proceeding ISBN 0306444003; https://catalog.nlm.nih.gov/permalink/01NLM_INST/1o1phhn/alma997246103406676

155. Brawner, M., Fornwald, J., Rosenberg, M., Poste, G. and Westpheling, J. (1991) Streptomyces: a host for heterologous gene expression. Current Opinion in Biotechnology, Vol. 2, pp. 674-81. Current Biology Ltd., London.

156. Brawner, M., Fornwald, J., Rosenberg, M., Poste, G. and Westpheling, J. (1990) Heterologous gene expression in streptomyces. Genetics of Industrial Microorganisms, pp. 85-93. Heslot, H., Davies, J., Florent, J., Bobichon, L., Durand, G., Penasse, L., (1990) Editors. Societe Francaise de Microbiologie, Strasbourg.

157. Gregoriadis, G., Allison, A., and Poste, G. (1990) Editors. Vaccines: recent trends and progress. NATO ASI Series. Series A: Life Sciences, Vol. 215. Plenum Press, New York.

158. Harris, T., Poste, G. (1991). Pharmaceutical applications. Current Opinion in Biotechnology, Vol. 2, No. 2, pp. 211-214. (ed. J. Davies) Current Biology Ltd., London.

159. Hanna, N., Poste, G. (1991). Inflammation. Encyclopedia of Human Biology, Vol. 4, pp. 469-477. Academic Press, New York.

160. Ruffolo, Jr., R.R., Brooks, D., Huffman, W., Poste, G., (1991) From vasopressin antagonist to agonist: a saga of surprise! Drug News & Perspectives, 4(4), 217-222.

161. Poste, G., The importance of the national climate as a stimulus to research in the USA. Reprinted from Creating the Right Environment for Drug Discovery, Edited by Stuart R. Walker, pp. 105-121. The Ciba Foundation, London. Quay Publishing.

162. Gregoriadis, G., Allison, A.C., Poste, G. (1989) Editors. Targeting of drugs 2: optimization strategies. NATO ASI Series. Series A: Life Sciences Vol. 199. Plenum Press, New York.

163. Hook, J., and Poste, G. (1990) Editors. Protein Design and the Development of New Therapeutics and Vaccines. Plenum Press, New York.

164. Greig, R., and Poste, G. (1990) Glycoconjugates as drugs. Glycobiology, pp. 173-193.

165. Badger, A.M., Griswold, D.E., Poste, G., Hanna, N. (1990) Histamine modulation of murine suppressor cell function. Histamine & H2 Antagonists in Inflammation and Immunodeficiency, pp. 3-21.

166. Gregoriadis, G., Allison, A.C., Poste, G. (1989) Editors. Immunological Adjuvants and Vaccines. NATO ASI Series. Series A: Life Sciences, Vol. 179.

167. Moyer, M.P., and Poste, G. (1989) Editors. Colon Cancer Cells. Academic Press, New York.

168. Bugelski, P.J., Gennaro, D.E., Poste, G., Hoffstein, S.T. (1989) A new cytochemical method for ultrastructural detection of liposomes in tissues in vivo. Journal of Histochemistry and Cytochemistry, 37(6) 843-851.

169. Pritchard, M.L., Rieman, D., Feild, J., Kruse, C., Rosenberg, M., Poste, G., Greig, R.G., Ferguson, B.Q. (1989) A truncated v-abl-derived tyrosine-specific tyrosine kinase expressed in escherichia-coli. Biochem J., 257(2), 321-329.\

170. Poste, G. (1989) Biotechnology: A new horizon for pharmacy. U.S.Pharmacist 14, 76-83.

171. Fidler, I., Poste, G., Murine Melanoma Metastasis. (1988) ISI Atlas of Science: Immunology, pp. 133-137.

172. Gregoriadis, G., Poste, G. (1988) Editors. Targeting of Drugs: Anatomical and Physiological Considerations. (1988) NATO ASI Series. Series A: Life Sciences, Vol. 155.

173. Poste, G., Greig, R. (1988) New-wave cancer therapy: Disease-specific strategies. The Scientist, 2(19), 1-14.

174. Caltabiano, M.M., Poste, G., Greig, R.G. (1988) Isolation and immunological characterization of the mammalian 32-/34- kDa stress protein. Experimental Cell Research, 178, 31-40.

175. Kruse, C.H., Holden, K.A., Offen, P.H., Pritchard, M.L., Feild, J.A., Rieman, D., Bender, P.E., Greig, R.G. and Poste, G. (1988) Synthesis and evaluation of multisubstrate inhibitors of an oncogene-encoded tyrosine-specific protein kinase. J. Medicinal Chemistry. 31, 1762-1772

176. Caltabiano, M.M., Poste, G., and Greig, R.G. (1988) Induction of the 32-kDa human stress protein by auranofin and related triethylphosphine gold analogs. Biochem. Pharmacol. 37, 21, 4089-4093.

177. Kirsh, R., Goldstein, R., Tarloff, J., Parris, D., Hook, J., Hanna, N., Bugelski, P., and Poste, G. (1988) An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. The Journal of Infectious Diseases, 158, 5, 1065-1070.

178. Young, J.F., and Poste, G. (1988) The prospects for a human malaria vaccine. Trends in Biotechnology 6, 63-68.

179. Trainer, D., Kline, T., Hensler, G., Greig, R., and Poste, G. (1988) Clonal analysis of the malignant properties of B16 melanoma cells treated with the DNA hypomethylating agent 5-azacytidine. Clin. Expl. Metastasis 6, 185-200.

180. Poste, G. and Crooke, S.T. (1988) Editors. Cellular and molecular aspects of inflammation. New Horizons in Therapeutics Volume 5, Plenum Press, New York.

181. Trainer, D.L., Kline, T., McCabe, F.L., Faucette, L.F., Feild, J., Chaikin, M., Anzano, M., Rieman, D., Hoffstein, S., Li, D., Gennaro, D., Buscarino, C., Lynch, M., Poste, G., and Greig, R. (1988) Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int. J. Cancer 41, 287-296.

182. Bailey, D.S., Nambi, P., Bryant, S.L., Clark, R.K., Trainer, D., Poste, G., Greig, R (1987) Signal transduction and differentiation of colon carcinoma cells. J. Cell Biol., Vol. 105.

183. Greig, R.G, Anzano, M., Tainer, D., Poste, G. (1987) Growth-regulation in colon-carcinoma. Journal of Cellular Biochemistry. S11D, p. 85.

184. Trainer, D.L., Clark, R., Feild, J., Chaikin, M., Kline, T., Watt, R., Poste, G., Greig, R. (1987) Oncogene expression in primary and metastatic human-colon carcinoma. Gastroenterology, 92(5) 1673.

185. Clark, R.K., Bailey, D.S., Bryant, S.L., Trainer, D.L., Poste, G., Greig, R. (1987) Differentiation and carbohydrate expression in colon-carcinoma. Proceedings of the American Association of Cancer Research. March, Vol. 28, 39.

186. Bailey, D.S., Kline, T., Clark, R.K., Hoffstein, S., Poste, G., Greig, R. (1987) Glycoprotein synthesis by Human Colon Carcinoma Cells In Vitro and As Xenografts in Nude Mice. Biochem. Soc. Trans., 15(3), 385.

187. Griswold, D.G., Webb, E.F., Godfrey, R., DiMartino, M.J., Sarau, H., Poste, G. and Hanna, N. (1987) SK&F 86002: A novel anti-inflammatory agent producing inhibition of lipoxygenase- and cyclooxygenase-mediated arachidonic acid metabolism. Biochem. Pharmacol. 36, 3463-3470.

188. Kirsh, R., Poste, G. (1987) Liposome-Mediated Macrophage Activities. Methods in Enzymology 149, 147-157.

189. Poste, G. and Crooke, S.T. (1987) Editors. New Frontiers in the Study of Gene Functions. New Horizons in Therapeutics, Plenum Press, New York.

190. Poste, G. (1987) Industrial biotechnology in Europe-Issues for public policy. A Book Review The Scientist 1, 23.

191. Koestler, T., Johnson, W., Rieman, D., Dalton, B., Greig, R., and Poste, G. (1987) Differential expression of murine macrophage-mediated tumor cytotoxicity induced by interferons. Cancer Research 47, 2804-2808.

192. Niewiarowska, A., Caltabiano, M.M., Bailey, D.S., Poste, G., and Greig, R.G. (1987) Alterations in lipid-linked oligosaccharide metabolism in human melanoma cells concomitant with induction of stress proteins. J. Biol. Chem. 262, 14815-14820.

193. Bugelski, P.J., Corwin, S.P., North, S.M., Kirsh, R.L., Nicolson, G.L. and Poste, G. (1987) Macrophage content of spontaneous metastases at different stages of growth. Cancer Research 47, 4141-4145.

194. Bugelski, P.J., Kirsh, R., Buscarino, C., Corwin, S.P. and Poste, G. (1987) Recruitment of exogenous macrophages into metastases at different stages of tumor growth. Cancer Immunol. Immunotherap. 24, 93-98.

195. Dunnington, D.J., Buscarino, C., Gennaro, D., Greig, R., and Poste, G. (1987) Characterization of an animal model of metastatic colon carcinoma. Int. J. Cancer 39, 248-254.

196. Rees, R., Dalton, B., Young, J., Hanna, N., and Poste, G. (1987) Augmentation of human natural killer cell activity by influenza virus antigens produced in E. Coli. J. Biol. Res. Mod., 6, 9-87.

197. Lester, B.R., Stadel, J.M., Buscarino, C., Sheppard, J., Greig, R.G., and Poste, G. (1987) Reconstitution of the Gs protein from B16 melanoma clones of high and low experimental metastatic potential into S49 CYCmembranes. Biochemical and Biophysical Research Communications 147, 443-451.

198. DiMartino, M.J., Griswold, D.E., Berkowitz, B.A., Poste, G., and Hanna, N. (1987) Pharmacologic characterization of the antiinflammatory properties of a new dual inhibitor of lipoxygenase and cyclooxygenase. Agents and Actions Vol. 20, 113- 123.

199. Wright, B., Zeidman, I., Greig, R., Poste, G. (1986) Calcium fluxes and calmodulin inhibitors in macrophage activation. Cellular Immunology, 100(2), 586-587.

200. Caltabiano, M.M., Koestler, T.P., Poste, G., Greig, R.G. (1986) Compound used in the therapy of rheumatoid-arthritis. Biochemical and Biophysical Research Communications, 138(3) 1074-1080.

201. Poste, G., Greig, R. (1986) The Cell-Surface and Cancer Metastasis. American Zoologist, 26(3), 567.

202. Greig, Russell G., and Poste, G. (1986) Biological Membranes and Malignancy: An Overview of Pharmacological Opportunities. In: Annals of the New York Academy of Sciences, Vol. 488.

203. Kirsh, R., and Poste, G. (1986) Liposome targeting to macrophages: opportunities for treatment of infectious diseases. In: Infections in the Immunocompromised Host-Laboratory Diagnosis and Treatment. Eds. P. Actor, A. Evangelista, J. Poupard and E. Hinks, Plenum Press, New York. pp 171-184.

204. Kirsh, R., and Poste, G. (1986) Liposome targeting to macrophages: opportunities for treatment of infectious diseases. In: Infections in the Immunocompromised Host-Laboratory Diagnosis and Treatment. Eds. P. Actor, A. Evangelista, J. Poupard and E. Hinks, Plenum Press, New York. pp 171-184.

205. Gregoriadis, G., Senior, J., and Poste, G. (1986) Editors. Targeting of drugs with synthetic systems. NATO ASI Series. Plenum Press, New York, Vol. 113.\

206. Kirsh, R. and Poste, G. (1986) Liposome mediated drug delivery to mononuclear phagocytes in vivo: Applications in antimicrobial therapy. In: Medical Applications of Liposomes. (ed. K. Yagi) pp. 99-104 Karger, Basel.

207. Horan, P.K., Slezak, D. and Poste, G. (1986) Improved flow cytometric analysis of leukocyte cell subsets: Simultaneous identification of five cell subsets using two color immunofluorescence. Proc. Nat. Acad. Sci. USA, 82, 8361-8365.

208. Lester, B. R., Greig, R. G., Buscarino, C. Sheppard, J. R., Corwin, S. P. and Poste, G. (1986) cAMP metabolism in B16 Melanoma clones during the formation of experimental and spontaneous metastases. Int. J. Cancer 38, 405-411.

209. S. Steinberg) Plenum Publishing Corp.

210. Poste, G., and Greig, R. (1986) The Cell Surface and Cancer Metastasis. Developmental Biology Volume 3, 15-31 (ed. M.

211. Van Alstine, J.M., Sorensen, P., Webber, T.J., Greig, R., Poste, G. and Brooks, D.E. (1986) Heterogeneity in the surface properties of B16 melanoma cells from sublines with differing metastatic potential detected via two polymer aqueous phase partition. Experimental Cell Research 164, 366-378.

212. Caltabiano, M., Koestler, T., Poste, G. and Greig, R. (1986) Induction of 32- and 34-kDa stress proteins by sodium arsenite, heavy metals, and thiol-reactive agents. J. Biol. Chem. 261, 13381-13386.

213. Caltabiano, M. M., Koestler, T. P., Poste, G. and Greig, R. (1986) Induction of mammalian stress proteins by triethylphosphine gold compound used in the therapy of rheumatoid arthritis. Biochem. Biophys. Res. Comm. 138, 1074- 1080.

214. Poste, G. (1986). Cell surface alterations and the metastatic behavior of tumor cells. In: Interaction of Cells with Natural and Foreign Surfaces. (ed. N. Crawford) Plenum Press, New York.

215. Kirsh, R. and Poste, G. (1986) Macrophage-mediated tumor cell destruction: opportunities for treatment of metastatic disease. In: Receptors in Tumor Biology. (ed. C. M. Chadwick) Marcel Dekker, New York.

216. Poste, G. and Crooke, S.T. (1986) Editors. New insights into cell and membrane transport processes. New Horizons in Therapeutics. Vol. 3. Plenum Press, New York.

217. Sheppard, J. R., Lester, B., Doll, J., Buscarino, C., Gonzales, E., Corwin, S., Greig, R. and Poste G. (1986) Biochemical regulation of adenylate cyclase in murine melanoma clones with different metastatic properties. Int. J. Cancer 37, 713-722.

218. Nicolson, G.L., Fidler, I.J. and Poste, G. (1986) The effects of tertiary amine local anesthetics on the blood-borne implantation and cell surface properties of metastatic mouse melanoma cells. J. Nat. Cancer Inst. 76, 511-519.

219. Lee, J., Rebar, L., Young, P., Ruscetti, F., Hanna, N. and Poste, G. (1986) Identification and characterization of a human T cell line-derived lymphokine with MAF-like activity distinct from gamma interferon. J. Immunol. 136, 1322-1328.

220. Poste, G. (1986) Pathogenesis of metastatic disease: Implications for current therapy and for the development of new therapeutic strategies. Cancer Treatment Reports. 70, 183-199.

221. Poste, G. and Greig, R. (1986) Experimental Models for Studying the Pathogenesis and Therapy of Metastatic Disease. In: Mechanisms of Cancer Metastasis: Potential therapeutic implications. (ed. K. V. Honn) pp. 41-68 Martinus Nijhoff, Boston.

222. Poste, G. and Crooke, S.T. (1985) Editors. Mechanisms of Receptor Regulation. New Horizons in Therapeutics, Vol. 2. Plenum Press, New York.

223. Colloids and Surfaces 14, 339-348

224. Kirsh, R. and Poste, G. (1985) Liposome mediated delivery of biological response modifiers (BRM) to macrophages in vivo: A new strategy for therapy of neoplastic disease.

225. Poste, G. (1985) The pharmaceutical industry and health care in the third world. Biotechnology 3, 704-706.

226. Griswold, D.E., Antell, L., Bender, P.E., Hanna, N. and Poste, G. (1985) Induction of suppressor cells, interleukin 2 production and mitogenesis with monomeric concanavalin A: different actions of tetrameric and monomeric concanavalin A. Mol. Immunol. 22, 1311-1316.

227. Muirhead, K., Bender, P., Hanna, N. and Poste, G. (1985) Binding of histamine and histamine analogs to lymphocyte subsets analyzed by flow cytometry. J. Immunol. 135, 4120-4128.

228. Greig, R.G., Caltabiano, L., Feild, J., Reid, Jr., R. and Poste, G. (1985) Alterations in the phosphoprotein composition of tumor cell clones induced by cell culture techniques used routinely in assessing metastatic behavior in vivo. Int. J. Cancer 35, 367-375.

229. Koestler, T., Badger, A., Rieman, D., Greig, R. and Poste, G. (1985) Induction by immunomodulatory agents of a macrophage antigen recognized by monoclonal antibody 158.2 and correlation with macrophage function. Cellular Immunology 96, 113-125.

230. Wright, B., Zeidman, I., Greig, R. and Poste, G. (1985) Inhibition of macrophage activation by calcium channel blockers and calmodulin antagonists. Cellular Immunology 95, 46-53.

231. Poste, G. (1985) Current concepts of cancer metastasis. Transactions and Studies of the College of Physicians of Philadelphia series 5, 7, 239-252.

232. Trainer, D., Kline, T., Mallon, F., Greig, R. and Poste, G. (1985) Effect of 5-azacytidine on DNA methylation and the malignant properties of B16 melanoma cells. Cancer Research 45, 6124-6130.

233. Fidler, I.J. and Poste, G. (1985) The cellular heterogeneity of malignant neoplasms: Implications for adjuvant chemotherapy. Seminars in Oncology, 12, 207-221. https://pubmed.ncbi.nlm.nih.gov/4048964/

234. Greig, R.G., Koestler, T.P., Trainer, D.L., Corwin, S., Miles, L., Kline, T., Sweet, R., Yokoyama, S. and Poste, G. (1985) Tumorigenic and metastatic properties of "normal" and ras-transfected NIH/3T3 cells. Proc. Nat. Acad. Sci., USA 82, 3698-3701.

235. Ferguson, B. Pritchard, L. Feild, J., Reiman, D., Greig, R., Poste, G. and Rosenberg, M. (1985) Isolation analysis of an Abelson murine leukemia virus-encoded tyrosine-specific kinase produced in E. coli. J. Biol. Chem. 260, 3652-3657.

236. Bugelski, P.J., Kirsh, R., Corwin, S., Sowinski, J. and Poste, G. (1985) Changes in the macrophage content of lung metastases at

different stages in tumor growth. Am. J. Pathol. 118, 419-424.

237. Ravetch, J.V., Young, J. and Poste, G. (1985) Molecular Genetic Strategies for the Development of Anti-Malarial Vaccines. Biotechnology 3, 729-740.

238. Poste, G. (1985) Drug Targeting in Cancer Therapy. In: Receptor-Mediated Targeting of Drugs. (eds. G. Gregoriadis, J. Senior, G. Poste and A. Trouet) pp. 427-474. Plenum Press, New York.

239. Greig, R.G., Lester, B., Sorensen, P., Buscarino, C. and Poste, G. (1985) Hormonal regulation of B16 melanoma metastasis. In: Treatment of Metastasis: Problems and Prospects. (eds. K. Hellmann and S.A. Eccles.) pp. 121-124. Taylor and Francis, London.

240. Muirhead, K.A., Horan, P.K. and Poste, G. (1985) Flow Cytometry: Present and future. Biotechnology 3, 337-356.

241. Griswold, Don E., Lee, J. C., Poste, G. and Hanna, N. (1985) Modulation of macrophage-lymphocyte interactions by the antiarthritic gold compound, auranofin. J. Rheumatol. 12, 490-497.

242. Poste, G. (1985) Tumor cell heterogeneity and the pathogenesis of cancer metastasis. In: Basic Mechanisms and Clinical Treatment of Tumor Metastasis. (eds. Torisu, M and Yoshida, T.) pp. 79-100. Academic Press, New York. https://doi.org/10.1038/283139a0

243. Poste, G., (1984) The mystery of metastasis: What we know, so far. Your Patient and Cancer April, 59-61.

244. Koestler, T.P., Kirsh, R., Kline, T., Rieman, D., Greig, R. and Poste, G. (1984) Production of C3 as a marker of lymphokine-mediated macrophage activation. Cell. Immunol. 87, 1-14.

245. Koestler, T.P., Rieman, D., Muirhead, K., Greig, R.G. and Poste, G. (1984) Identification and characterization of a monoclonal antibody to an antigen expressed on activated macrophages (lymphokine/hybridoma/cell surface antigens/immunofluorescence/macrophage-mediated cytotoxicity. Proc. Nat. cad. Sci. USA. 81, 4505-4509.

246. Poste, G. (1984) New insights into receptor regulation. J. Applied Physiol. 57, 1297-1305.

247. Kirsh, R. and Poste, G. (1984) Liposomes and targeted drug delivery to macrophages: A potential system for improved therapy of microbial infections. Clin. Immunol. Newsletter 5, 168-171.

248. Poste, G. (1984) Hype, Hope and Honesty: Reporting of Cancer Discoveries by the Media. Biotechnology 2, 1096.

249. Poste, G., Kirsh, R. and Bugelski, P. (1984) Liposomes as a drug delivery system in cancer therapy. In: Novel Approaches to Cancer Chemotherapy. (ed. P. Sunkara) pp. 165-230. Academic Press, New York. https://doi.org/10.1007/978-1-4684-4862-7_25

250. Poste, G. and Crooke, S.T. (1984) Editors. Dopamine Receptor Agonists. New Horizons in Therapeutics. Vol. 1. Plenum Press, New York.

251. Poste, G. (1984) Liposomes: fascination, frustration, feasibility and fantasy. In: Liposome Letters. (ed. A.D. Bangham) pp. 375-386. Academic Press, London.

252. Poste, G. and Nicolson, G.L. (1984) In vitro systems for studying the interaction of metastatic tumor cells with endothelial cells and subendothelial basement membranes. In: Biology of Endothelial Cells. (ed. E. A. Jaffe) pp. 438-448. Martinus Nijhoff, Boston.

253. Poste, G., Tzeng, J., Koestler, T., Corwin, S., and Greig, R. (1984) Interactions between tumor cell subpopulations in malignant tumors. In: Cancer Invasion and Metastasis: Biological and Therapeutic Aspects. (eds. G. Nicolson and L. Milas) pp. 223-244. Raven Press, New York.

254. Kirsh, R. and Poste, G. (1984) Macrophage activation in vivo: New approaches to the therapy of metastatic tumors. EOS J. Immunol. Immunopharmacol. IV, 32-35.

255. Griswold, D.E., Alessi, S., Badger, A.M., Poste, G. and Hanna, N. (1984) Inhibition of T suppressor cell expression by histamine type 2 (H2) receptor antagonists. J. Immunol. 132, 3054-3057.

256. Sheppard, J.R., Koestler, T., Corwin, S., Buscarino, C., Doll, J., Lester, B., Greig, R. and Poste, G. (1984) Experimental metastasis correlates with cyclic AMP accumulation in B16 melanoma clones. Nature 308, 544-547.

257. Kirsh, R. and Poste, G. (1984) Liposome encapsulation of biological response modifiers: Activation of tumoricidal macrophages. In: Liposome Technology (ed. G. Gregoriadis) Vol. 2, pp. 33-53. CRC Press, Boca Raton, Florida.

258. Poste, G., Kirsh, R. and Koestler, T. (1984) The challenge of liposome targeting in vivo. In: Liposome Technology (ed. G. Gregoriadis) Vol. 3, pp.1-28. CRC Press, Boca Raton, Florida.

259. Poste, G. and Greig, R. (1983) The experimental and clinical implications of cellular heterogeneity in malignant tumors. J. Cancer Res. Clin. Oncol. 106, 159-170.

260. Nicolson, G.L. and Poste, G. (1983) Tumor implantation and invasion at metastatic sites. Int. Rev. Exp. Pathol. 25, 77-181.

261. Poste, G. (1983) Whatever happened to the industry I was told to distrust. Immunology Today 4, 133-136.

262. Kirsh, R. and Poste, G. (1983) Stimulation of host resistance to metastatic tumors by macrophage activating agents encapsulated in liposomes. In: Host Defenses to Intracellular Pathogens. (ed. T.K. Eisenstein) Adv. Exp. Biol. Med. Vol. 162, pp. 69-75. Raven Press, New York.

263. Nicolson, G.L. and Poste, G. (1983) Tumor cell diversity and host responses in cancer metastasis. II. Host immune responses and therapy of metastases. In: Current Problems in Cancer. (ed. R.C. Hickey) Vol. 7, pp. 1-42. Yearbook Medical Publishers, Chicago.

264. Poste, G. (1983) Liposome targeting in vivo: problems and opportunities. In: Liposomes in Vivo. (eds. C. Nicolau and G. Poste). Biol. Cell. 47, pp. 19-38.

265. Poste, G. and Nicolson, G.L. (1983) Experimental systems for analysis of the surface properties of metastatic tumor cells. In: Biomembranes. (ed. A. Nowotny) Vol. 11, pp. 341-364. Plenum Press, New York.

266. Poste, G. and Kirsh, R. (1983) Site-specific (targeted) drug delivery in cancer therapy. Biotechnology 1, 869-878.

267. Hanna, N., DiMartino, M., Griswold, D.E. and Poste, G. (1983) Immunology of auranofin. Current Clinical Practice 7, 60- 70.

268. Griswold, D.E., Badger, A.M., Bender, P.E., Sitrin, R.D., Antell, L., Greig, R.G. and Poste, G. (1983) Differential effects of intact subunits and nicked fragments of concanavalin A on immune functions in vitro and in vivo. J. Immunol. 131, 1626- 1628.

269. Badger, A., Brown, A.E. and Poste, G. (1983) The effect of cimetidine on antibody synthesis in vitro and in vivo. Immunology 48, 151-155.

270. Badger, A., Young, J. and Poste, G. (1983) Inhibition of phytohaemagglutinin-induced proliferation of human peripheral blood lymphocytes by histamine and histamine H1 and H2 agonists. Clin. Exp. Immunol. 51, 178-184.

271. Bugelski, P.J., Kirsh, R.L. and Poste, G. (1983) New histochemical method for measuring intratumoral macrophages and macrophage recruitment into experimental metastases. Cancer Research 43, 5493-5501.

272. Greig, R. G., Caltabiano, L., Reid, Jr., R., Feild, J. and Poste, G. (1983) Heterogeneity of protein phosphorylation in metastatic variants of B16 melanoma. Cancer Research 43, 6057-6065.

273. Poste, G. (1983) Tumor cell heterogeneity and the metastatic process. In: Understanding Breast Cancer: Clinical and Laboratory Concepts. (eds. M.A. Rich, J.C. Hager and P. Furmanski) pp. 119-143. Marcel Dekker, Inc., New York.

274. Poste, G. and Nicolson, G.L. (1982) Editors. Cell Surface Reviews, Volume 8. Membrane Reconstitution. Elsevier/North- Holland, Amsterdam. 360 pages.

275. Poste, G., Bucana, C. and Fidler, I.J. (1982) Stimulation of host response against metastatic tumors by liposome- encapsulated immunomodulators. In: Targeting of Drugs. (eds. G. Gregoriadis, J. Senior and A. Trouet) NATO Advanced Studies Institute Series, Vol. A47, pp. 261-284. Plenum Press, New York.

276. Poste, G. and Kirsh, R. (1982) Liposome-encapsulated macrophage activation agents and active non-specific immunotherapy of neoplastic disease. In: Cell Function and Differentiation, Part A. (ed. A. Evangelopoulos) pp. 309-319. Alan R. Liss, New York.

277. Fidler, I.J. and Poste, G. (1982) The heterogeneity of metastatic properties in malignant tumor cells and regulation of the metastatic phenotype. In: Tumor Cell Heterogeneity: Origins and Implications. (eds. A. Owens, Coffey, D. S., and S. Balin) pp. 127-145. Academic Press, New York.

278. I.J. Fidler) Vol. 1, pp. 141-199. Martinus Nijhoff, Amsterdam.

279. Poste, G. (1982) Experimental systems for analysis of the malignant pheno-type. In: Cancer and Metastasis Reviews. (ed.

280. Fidler, I.J. and Poste, G. (1982) Macrophages and Cancer Metastasis. In: Macrophages and Natural Killer Cells. Advances in Experimental Medicine and Biology, Vol. 155. (eds. S.J. Normann and E. Sorkin) pp. 65-75. Plenum Press, New York.

281. Nicolson, G.L. and Poste, G. (1982) Tumor cell diversity and host responses in cancer metastasis. I. Properties of metastatic cells. In: Current Problems in Cancer. (ed. R.C. Hickey) pp. 1-83. Yearbook Medical Publishers, Chicago.

282. Poste, G. (1982) Variation in the metastatic properties of cells from malignant tumors and the control of the metastatic phenotype. In: Tumour Progression and Markers. (ed. M. Price) pp. 197-210. Kugler Publications, Amsterdam.

283. Poste, G. (1982) Liposomes as a carrier system for improved delivery of biologically-active materials to cells in vitro and In vivo. In: Liposome Methodology. (eds. L.D. Leserman and J. Barbet) pp. 65-77. Inserm, Paris.

284. Brown, A.E., Badger, A.M. and Poste, G. (1982) The effect of cimetidine on immune cell function and host response to tumors. In: Current Concepts in Human Immunology and Cancer Immunomodulation. (ed. B. Serrou) pp. 513-519. Elsevier, Amsterdam.

285. Poste, G. (1982) Methods and models for studying tumor invasion. In: Tumor Invasion and Metastasis. (eds. L.A. Liotta and I.R. Hart) pp. 147-171. Martinus Nijhoff, Amsterdam.

286. Poste, G. and Fidler, I.J. (1982) Therapeutic amplification of macrophage-mediated destruction of tumor cells: An approach to cancer therapy that addresses the problem of tumor cell heterogeneity. In: Design of Models for Testing Cancer Therapeutic Agents. (eds. I.J. Fidler and R.J. White) pp. 225-238. Van Nostrand, New York.

287. Poste, G. and Fidler, I.J. (1982) Active non-specific immunotherapy of lung metastases by macrophages activating agents encapsulated in liposomes. In: Optimization of Drug Delivery, Alfred Benzon Symposium 17. (eds. H. Bundgaard, A. Bagger Hansen and H. Kofod) pp. 418-431. Munksgaard, Copenhagen.

288. Poste, G. (1982) Cellular heterogeneity in malignant neoplasms and the therapy of metastases. Ann. N.Y. Acad. Sci. 391, 34-48.

289. Sitrin, R.D., Antell, L.A., Griswold, D.E., Bender, P.E., Greig, R.G. and Poste, G. (1982) A high performance liquid chromatography assay for the rapid analysis of the subunit content of concanavalin A. Biochim. Biophys. Acta 717 (1) 175- 178.

290. Badger, A., Griswold, D.E., DiMartino, M.J. and Poste, G. (1982) Inhibition of antibody synthesis by histamine in concanavalin A-treated mice: The possible role of glucocorticosteroids J. Immunol. 129, 1017-1022.

291. Poste, G., Tzeng, J., Doll, J., Greig, R., Rieman, D. and Zeidman, I. (1982) Evolution of tumor cell heterogeneity during progressive growth of individual lung metastases. Proc. Nat. Acad. Sci. USA 79, 6574-6578.

292. Fidler, I.J. and Poste, G. (1982) Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease. Springer Semin. Immunopathol. 5, 161-174.

293. Poste, G. and Greig, R. (1982) On the genesis and regulation of cellular heterogeneity in malignant tumors. Invasion and Metastasis 2, 137-176.

294. Poste, G., Doll, J., Brown, A.E., Tzeng, J. and Zeidman, I. (1982) Comparison of the metastatic properties of B16 melanoma clones isolated from cultured cell lines,Cancer Research 42, 1412-1422. subcutaneous tumors, and individual lung metastases. Cancer Research 42, 2770- 2778.

295. Poste, G., Bucana, C., Raz, A., Bugelski, P., Kirsh, R. and Fidler, I.J. (1982) Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery.

296. Poste, G. and Flood, M.K. (1981) Cells transformed by temperature-sensitive mutants of avian sarcoma virus cause tumors in vivo at both permissive and nonpermissive temperatures. In: Readings in Mammalian Cell Culture. (ed. R. Pollack) pp. 351-362. Cold Spring Harbor Laboratory, New York.

297. G.P. Murphy, A.A. Sandberg and J.P. Karr) Part B, pp. 257-267. Alan R. Liss, New York.sulated within liposomes as a treatment for spontaneous metastasis. In: The Prostatic Cell: Structure and Function. (eds.

298. Fidler, I.J. and Poste, G. (1981) Activation of tumoricidal properties in murine macrophages by intravenous injection of muramyl dipeptide encap-

299. Fidler, I.J. and Poste, G. (1981) Treatment of spontaneous murine metas-tases by the systemic administration of liposomes containing macrophage-activating agents. In: Cancer: Achievements, Challenges and Prospects for the 1980s. (eds J.H. Burchemall and H.F. Oettgen) Vol. 2, pp. 77-89. Grune and Stratton, New York.

300. Poste, G. and Fidler, I.J. (1981) Stimulation of macrophage-mediated destruction of lung metastases by administration of immunomodulators encapsulated in liposomes. In: Liposomes, Drugs and Immunocompetent Cell Functions. (eds. C. Nicolau and A. Paraf) pp. 147-161. Academic Press, New York.

301. In: Manual of Macrophage Methodology. (eds. H.B. Herscowitz, H.T. Holden, J.A. Bellanti and A. Ghaffar) pp. 509-514. Marcel Dekker, New York.

302. Fidler, I.J. and Poste, G. (1981) Macrophage destruction of micrometastases.

303. Poste, G. and Fidler, I.J. (1981) Activation of macrophages by lymphocyte mediators encapsulated in liposomes. In: Manual of Macrophage Methodology. (eds. H.B. Herscowitz, H.T. Holden, J.A. Bellanti and A. Ghaffar) pp. 431-438. Marcel Dekker, New York.

304. Poste, G., Doll, J. and Fidler, I.J. (1981) Interactions among clonal subpopulations affect the stability of the metastatic phenotype in poly-clonal populations of B16 melanoma cells. Proc. Nat. Acad. Sci. USA 78, 6226-6230. https://pubmed.ncbi.nlm.nih.gov/6947225/

305. Hart, I.R., Fogler, W.E., Poste, G. and Fidler, I.J. (1981) Toxicity studies of liposome-encapsulated immunomodulators administered intravenously to dogs and mice. Cancer Immunol. Immunother. 10, 157-166.

306. Fidler, I.J., Raz, A., Fogler, W.E., Hoyer, L.C. and Poste, G. (1981) The role of plasma membrane receptors and the kinetics of macrophage activation by lymphokines encapsulated in liposomes. Cancer Research 41, 495-504.

307. Raz, A., Bucana, C., Fogler, W.E., Poste, G. and Fidler, I.J. Biochemical, morphological, and ultrastructural studies on the uptake of liposomes by murine macrophages. Cancer Research 41, 487-494.

308. Cotman, C., Poste, G. and Nicolson, G.L. (1980) Editors. Cell Surface Reviews, Volume 6. The Cell Surface and Neuronal Function. Elsevier/North-Holland, Amsterdam. 546 pp.

309. Fidler, I.J., Barnes, Z., Fogler, W.E., Kirsh, R., Bugelski, P. and Poste, G. (1982) Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators. Cancer Research 42, 496-501.

310. Fidler, I.J. and Poste, G. (1982) The biologic diversity of cancer metastases. Hospital Practice 17, 57-64.

311. Poste, G. and Nicolson, G.L. (1981) Editors. Cell Surface Reviews, Volume 7. Cytoskeletal Elements and Plasma Membrane Organization. Elsevier/North-Holland, Amsterdam. 349 pp.

312. Poste, G. and Flood, M.K. (1981) Cells transformed by temperature-sensitive mutants of avian sarcoma virus cause tumors in vivo at both permissive and nonpermissive temperatures. In: Readings in Mammalian Cell Culture. (ed. R. Pollack) pp. 351-362. Cold Spring Harbor Laboratory, New York.

313. Fidler, I.J. and Poste, G. (1981) Activation of tumoricidal properties in murine macrophages by intravenous injection of muramyl dipeptide encap- sulated within liposomes as a treatment for spontaneous metastasis. In: The Prostatic Cell: Structure and Function. (eds. G.P. Murphy, A.A. Sandberg and J.P. Karr) Part B, pp. 257-267. Alan R. Liss, New York.

314. Fidler, I.J. and Poste, G. (1981) Treatment of spontaneous murine metas-tases by the systemic administration of liposomes

containing macrophage-activating agents. In: Cancer: Achievements, Challenges and Prospects for the 1980s. (eds J.H. Burchemall and H.F. Oettgen) Vol. 2, pp. 77-89. Grune and Stratton, New York.

315. Poste, G. and Fidler, I.J. (1981) Stimulation of macrophage-mediated destruction of lung metastases by administration of immunomodulators encapsulated in liposomes. In: Liposomes, Drugs and Immunocompetent Cell Functions. (eds. C. Nicolau and A. Paraf) pp. 147-161. Academic Press, New York.

316. In: Manual of Macrophage Methodology. (eds. H.B. Herscowitz, H.T. Holden, J.A. Bellanti and A. Ghaffar) pp. 509-514. Marcel Dekker, New York.

317. Fidler, I.J. and Poste, G. (1981) Macrophage destruction of micrometastases.

318. Poste, G. and Fidler, I.J. (1981) Activation of macrophages by lymphocyte mediators encapsulated in liposomes. In: Manual of Macrophage Methodology. (eds. H.B. Herscowitz, H.T. Holden, J.A. Bellanti and A. Ghaffar) pp. 431-438. Marcel Dekker, New York.

319. Poste, G., Doll, J. and Fidler, I.J. (1981) Interactions among clonal subpopulations affect the stability of the metastatic phenotype in poly-clonal populations of B16 melanoma cells. Proc. Nat. Acad. Sci. USA 78, 6226-6230.

320. Hart, I.R., Fogler, W.E., Poste, G. and Fidler, I.J. (1981) Toxicity studies of liposome-encapsulated immunomodulators administered intravenously to dogs and mice. Cancer Immunol. Immunother. 10, 157-166.

321. Fidler, I. J., Raz, A., Fogler, W. E., Hoyer, L.C. and Poste, G. (1981) The role of plasma membrane receptors and the kinetics of macrophage activation by lymphokines encapsulated in liposomes. Cancer Research 41, 495-504.

322. Raz, A., Bucana, C., Fogler, W. E., Poste, G. and Fidler, I. J. Biochemical, morphological, and ultrastructural studies on the uptake of liposomes by murine macrophages. Cancer Research 41, 487-494.

323. Cotman, C., Poste, G. and Nicolson, G.L. (1980) Editors. Cell Surface Reviews, Volume 6. The Cell Surface and Neuronal Function. Elsevier/North-Holland, Amsterdam. 546 pp.

324. Fidler, I. J., Hart, I. R., Raz, A., Fogler, W. E., Kirsh, R. and Poste, G. (1980) Activation of tumoricidal properties in macrophages by liposome-encapsulated lymphokines: In vivo studies. In: Liposomes and Immunobiology. (eds. B. Tom and H. Six) pp. 109-118. Elsevier/North-Holland, Amsterdam.

325. Fidler, I. J., Raz, A., Fogler, W. E. and Poste, G. (1980) Pulmonary localization of intravenously injected liposomes. In: Recent Results in Cancer Research. (eds. G. Mathe and F.M. Muggia) Vol. 75, pp. 246-251. Springer Verlag, Berlin.

326. Poste, G., Kirsh, R., Raz, A., Sone, S., Bucana, C., Fogler, W.E. and Fidler, I.J. (1980) Activation of tumoricidal properties in macrophages by liposome-encapsulated lymphokines: In vitro studies. In: Liposomes and Immunobiology. (eds. B. Tom and H. Six) pp. 93-107. Elsevier/North-Holland, Amsterdam.

327. Poste, G. (1980) The influence of cell surface properties on the arrest of circulating melanoma cells. In: Tumor Cell Surfaces and Malignancy. (eds. R.O. Hynes and C.F. Fox) pp. 737-745. Alan R. Liss, New York.

328. Poste, G. (1980) The interaction of lipid vesicles (liposomes) with cultured cells and their use as carriers for drugs and macromolecules. In: Liposomes in Biological Systems. (eds. G. Gregoriadis and A.C. Allison) pp. 101-151. J. Wiley, New York.

329. Poste, G. (1980) Surface molecules and tumour-cell metastatic properties. Biochem. Soc. Trans. 8, 695-697.

330. the plasma membrane of cultured cells. Exp. Cell Research 129, 393-408.

331. Poste, G., Lyon, N.C., Macander, P., Porter, C.W., Reeve, P. and Bachmeyer, H. (1980) Liposome-mediated transfer of integral membrane glycoproteins into

332. Fidler, I.J., Raz, A., Fogler, W.E., Kirsh, R., Bugelski, P. and Poste, G. (1980) Design of liposomes to improve delivery of macrophage augmenting agents to alveolar macrophages. Cancer Research 40, 4460-4466.

333. Poste, G., Doll, J., Hart, I.R. and Fidler, I.J. (1980) In vitro selection of murine B16 melanoma variants with enhanced tissue-invasive properties. Cancer Research 40, 1636-1644.

334. Sone, S., Poste, G. and Fidler, I.J. (1980) Rat alveolar macrophages are susceptible to activation by free and liposome- encapsulated lymphokines. J. Immunol. 124, 2197-2202.

335. Poste, G. and Fidler, I.J. (1980) The pathogenesis of cancer metastasis. Nature 283, 139-146. https://doi.org/10.1038/283139a0

336. Poste, G. and Nicolson, G.L. (1980) Arrest and metastasis of blood-borne tumor cells are modified by fusion of plasma membrane vesicles from highly metastatic cells. Proc. Nat. Acad. Sci. USA 77, 399-403. https://doi.org/10.1073/pnas.77.1.399

337. Papahadjopoulos, D., Poste, G. and Vail, W.J. (1979) Studies on membrane fusion with natural and model membranes. In: Methods in Membrane Biology. (ed. E. Korn) pp. 1-121. Plenum Press, New York.

338. Poste, G. (1979) The surface properties of invasive and metastatic tumour-cell populations. British J. Cancer 39, 467-469.

339. Poste, G. (1979) The tumoricidal properties of inflammatory tissue macrophages and multinucleate giant cells. Am. J. Pathol. 96, 595-608.

340. Nicolson, G.L. and Poste, G. (1979) Lectin-mediated agglutination of murine lymphoma cells: cell surface deformability and reversibility of agglutination by saccharides. Biochim. Biophys. Acta 554, 520-531.

341. Poste, G. and Flood, M.K. (1979) Cells transformed by temperature-sensitive mutants of avian sarcoma virus cause tumors in vivo at both permissive and nonpermissive temperatures. Cell 17, 789-800.
342. Poste, G. and Kirsh, R. (1979) Rapid decay of tumoricidal activity and loss of responsiveness to lymphokines in inflammatory macrophages. Cancer Research 39, 2582-2590.
343. Poste, G., Kirsh, R., Fogler, W. and Fidler, I.J. (1979) Activation of tumoricidal properties in mouse macrophages by lymphokines encapsulated in liposomes. Cancer Research 39, 881-892.
344. Poste, G., Allen, H. and Matta, K.L. (1979) Cell surface receptors for lymphokines. II. Studies on the carbohydrate composition of the MIF receptor on macrophages using synthetic saccharides and plant lectins. Cell. Immunol. 44, 89-98.
345. Poste, G., Kirsh, R. and Fidler, I.J. (1979) Cell surface receptors for lymphokines. I. The possible role of glycolipids as receptors for macrophage migration inhibitory factor (MIF) and macrophage activation factor (MAF). Cell. Immunol. 44, 71-88.
346. Poste, G. and Nicolson, G.L. (1978) Editors. Cell Surface Reviews, Volume 5. Membrane Fusion. Elsevier/North- Holland, Amsterdam. 862 pages.
347. Poste, G., Reeve, P. and Bachmeyer, H. (1978) Interaction of lipid vesicles containing paramyxovirus envelope glycoproteins with cultured cells. In: Negative Strand Viruses and the Host Cell. (eds. B.W.J. Mahy and R.D. Barry) pp. 815-823. Academic Press, New York.
348. Poste, G. and Lyon, N. (1978) Enucleation of cultured animal cells by cytochalasin B. In: Cytochalasins - Biochemical and Cell Biological Aspects. (ed. S. Tanenbaum) pp. 161-189. Elsevier/North-Holland, Amsterdam.
349. Poste, G. and Pasternak, C.A. (1978) Virus-induced cell fusion. In: Membrane Fusion. (eds. G. Poste and G.L. Nicolson) Cell Surface Reviews, Vol. 5, pp. 305-367. Elsevier/North-Holland, Amsterdam.
350. Poste, G. and Papahadjopoulos, D. (1978) The influence of vesicle membrane properties on the interaction of lipid vesicles with cultured cells. Ann. N.Y. Acad. Sci. 308, 164-184.
351. Nicolson, G.L. and Poste, G. (1978) Mechanism of resistance to ricin toxin in selected mouse lymphoma cell lines. J. Supramolec. Structure 8, 235-245. Biochim. Biophys. Acta 510, 256-263.
352. Poste, G., Porter, C.W. and Papahadjopoulos, D. (1978) Identification of a potential artifact in the use of electron microscope autoradiography to localize saturated phospholipids in cells. Cell. Immunol. 38, 131-146.
353. Fidler, I.J., Roblin, R.O. and Poste, G. (1978) In vitro tumoricidal activity of macrophages against virus-transformed lines with temperature-dependent transformed phenotypic characteristics.
354. Poste, G. and Nicolson, G.L. (1977) Editors. Cell Surface Reviews, Volume 4. The Synthesis, Assembly and Turnover of Cell Surface Components. Elsevier/North-Holland, Amsterdam. 883 pages.
355. Poste, G. and Nicolson, G.L. (1977) Editors. Cell Surface Reviews, Volume 3. Dynamic Aspects of Cell Surface Organization. Elsevier/North-Holland, Amsterdam. 750 pages.
356. Poste, G. and Nicolson, G.L. (1977) Editors. Cell Surface Reviews, Volume 2. Virus Infection and the Cell Surface. Elsevier/North-Holland, Amsterdam. 350 pages.
357. Nicolson, G.L., Poste, G. and Ji, J.H. (1977) The dynamics of cell membrane organization. In: Dynamic Aspects of Cell Surface Organization. (eds. G. Poste and G.L. Nicolson) Cell Surface Reviews, Vol. 3, pp. 1-73. Elsevier/North-Holland, Amsterdam.
358. Nicolson, G.L., Giotta, G., Lotan, R., Neri, A. and Poste, G. (1977) Modifications in transformed and malignant tumor cells. In: International Cell Biology. (eds. B.R. Brinkley and K.R. Porter) pp. 138-148. Rockefeller University Press, New York.
359. Poste, G. (1977) The cell surface and metastasis. In: Cancer Invasion and Metastasis: Biologic Mechanisms and Therapy. (ed. S.B. Day) pp. 19-47. Raven Press, New York.
360. Papahadjopoulos, D., Vail, W.J., Newton, C., Nir, S., Jacobson, K., Poste, G. and Lazo, R. (1977) Studies on membrane fusion. III. The role of calcium-induced phase changes. Biochim. Biophys. Acta 465, 579-598.
361. Nicolson, G. L. and Poste, G. (1976) Cell shape changes and transmembrane receptor uncoupling induced by tertiary amine local anesthetics. J. Supramolecular Structure 5, 65-72.
362. Poste, G. and Nicolson, G.L. (1976) Editors. Cell Surface Reviews, Volume 1. The Cell Surface in Animal Embryogenesis and Development. Elsevier/North-Holland, Amsterdam. 766 pages.
363. Poste, G. (1976) Changes in cell surface membranes associated with malignant transformation. In: Biological Handbooks: Cell Biology. (eds. P.L. Altman and D.D. Katz) Vol. 1, pp. 134-138. Federation of American Societies for Experimental Biology, Bethesda, Maryland.
364. Poste, G., Papahadjopoulos, D. and Vail, W.J. (1976) Lipid vesicles as carriers for introducing biologically active materials into cells. In: Methods in Cell Biology. (ed. D.M. Prescott) Vol. 14, pp. 33-71. Academic Press, New York.
365. D.M. Prescott) Vol. 14, pp. 23-32. Academic Press, New York.
366. Poste, G. and Papahadjopoulos, D. (1976) Fusion of mammalian cells by lipid vesicles. In: Methods in Cell Biology. (ed.
367. Poste, G., Alexander, D. and Reeve, P. (1976) Enhancement of virus-induced cell fusion by phytohemagglutinin. In: Methods in Cell

Biology. (ed. D.M. Prescott) Vol. 14, pp. 1-10. Academic Press, New York.

368. Nicolson, G. L. and Poste, G. (1976) Medical Progress. The cancer cell: Dynamic aspects and modifications in cell- surface organization. (Second of Two Parts) New England J. Med. 295, 253-258.

369. Nicolson, G. L. and Poste, G. (1976) Medical Progress. The cancer cell: Dynamic aspects and modifications in cell- surface organization. (First of Two Parts) New England J. Med. 295, 197-203.

370. Poste, G. and Weiss, L. (1976) Some considerations on cell surface alterations in malignancy. In: Fundamental Aspects of Metastasis. (ed. L. Weiss) pp. 25-47. Elsevier/North-Holland, Amsterdam.

371. Weiss, L. and Poste, G. (1976) The tumor cell periphery. In: Scientific Foundations of Oncology. (eds. T. Symington and R.L. Carter) pp. 25-35. Heinemann, London.

372. Papahadjopoulos, D., Poste, G., Vail, W.J. and Biedler, J.L. (1976) Use of lipid vesicles as carriers to introduce antinomycin D into resistant tumor cells. Cancer Research 36, 2988-2994.

373. II. Induction of fusion in pure phospholipid membranes by calcium ions and other divalent metals. Biochim. Biophys. Acta 448, 265-283.

374. Papahadjopoulos, D., Vail, W.J., Pangborn, W.A. and Poste, G. (1976) Studies on membrane fusion.

375. Papahadjopoulos, D., Hui, S., Vail, W.J. and Poste, G. (1976) Studies on membrane fusion. I. Interactions of pure phospholipid membranes and the effect of myristic acid, lysolecithin, proteins and dimethylsulfoxide. Biochim. Biophys. Acta 448, 245-264.

376. Jacobson, K., Derzko, Z., Wu, E.-S., Hou, Y. and Poste, G. (1976) Measurement of the lateral mobility of cell surface components in single, living cells by fluorescence recovery after photobleaching. J. Supramolec. Structure 5, 565-576.

377. Poste, G. and Papahadjopoulos, D. (1976) Drug-containing lipid vesicles render drug-resistant tumour cells sensitive to actinomycin D. Nature 261, 699-701.

378. Poste, G. and Papahadjopoulos, D. (1976) Lipid vesicles as carriers for introducing materials into cultured cells: Influence of vesicle lipid composition on mechanism(s) of vesicle incorporation into cells. Proc. Nat. Acad. Sci. USA 73, 1603-1607.

379. Jacobson, K., Wu, J. and Poste, G. (1976) Measurement of the translational mobility of concanavalin A in glycerol-saline solutions and on the cell surface by fluorescence recovery after photobleaching. Biochim. Biophys. Acta 433, 215-222.

380. Poste, G. and Nicolson, G. L. (1976) Calcium ionophores A23187 and X537A affect cell agglutination by lectins and capping of lymphocyte surface immunoglobulins. Biochim. Biophys. Acta 426, 148-155.

381. Nicolson, G. L., Smith, J. R. and Poste, G. (1976) Effects of local anesthetics on cell morphology and membrane- associated cytoskeletal organization in BALB/3T3 cells. J. Cell Biol. 68, 395-402.

382. Poste, G. and Waterson, A.P. (1975) Cell fusion by Newcastle disease virus. In: Negative Strand Viruses. (eds. B.W.J. Mahy and R.D. Barry) Vol. 2, pp. 905-922. Academic Press, London.

383. M.G. Brush and R.W. Taylor) pp. 87-108. Balliere Tindall, London.

384. Poste, G. and Waterson, A.P. (1975) Herpesvirus infection and cervical cancer. In: Gynaecological Malignancy. (eds.

385. Poste, G. (1975) Interaction of concanavalin A with the surface of virus-infected cells. In: Concanavalin A. (eds. T.K. Chowdhury and A.K. Weiss) pp. 117-152. Plenum Press, New York.

386. Weiss, L., Subjeck, J.R. and Poste, G. (1975) Some electrical properties of the peripheries of murine 3T3 cells with respect to viral transformation and reversion. Int. J. Cancer 16, 914-921.

387. Poste, G., Papahadjopoulos, D. and Nicolson, G.L. (1975) Local anesthetics affect transmembrane cytoskeletal control of mobility and distribution of cell surface receptors. Proc. Nat. Acad. Sci. USA 72, 4430-4434.

388. Papahadjopoulos, D. and Poste, G. (1975) Calcium-induced phase separation and fusion in phospholipid membranes. Biophys. J. 15, 945-948.

389. Poste, G., Papahadjopoulos, D., Jacobson, K. and Vail, W.J. (1975) Effects of local anesthetics on membrane properties. II. Enhancement of the susceptibility of mammalian cells to agglutination by plant lectins. Biochim. Biophys. Acta 394, 520-539.

390. Papahadjopoulos, D., Jacobson, K., Poste, G. and Shepard, G. (1975) Effects of local anesthetics on membrane properties. I. Changes in the fluidity of phospholipid bilayers. Biochim. Biophys. Acta 394, 504-519.

391. Papahadjopoulos, D., Vail, W.J., Jacobson, K. and Poste, G. (1975) Cochleate lipid cylinders: Formation by fusion of unilamellar lipid vesicles. Biochim. Biophys. Acta 394, 483-491.

392. Poste, G., Papahadjopoulos, D., Jacobson, K. and Vail, W.J. (1975) Local anaesthetics increase susceptibility of untransformed cells to agglutination by concanavalin A. Nature 253, 552-554.

393. Poste, G. (1975) Production of a serine-protease with macrophage migration inhibitory factor activity by virus- transformed cells and human tumor cell lines. Cancer Research 35, 2558-2566.

394. Poste, G. (1975) Production of macrophage migration inhibitory factor(s) (MIF) by virus-transformed cells. Exp. Cell Res. 92, 283-290.

395. Weiss, L., Poste, G., MacKearnin, A. and Willett, K. (1975) Growth of mammalian cells on substrates coated with cellular microexudates. I. Effect on cell growth at low population densities. J. Cell Biol. 64, 135-145.

396. Papahadjopoulos, D., Poste, G. and Mayhew, E. (1975) Interaction between cells, liposomes and micelles. Biochemical Society Transactions 3, 606-608.

397. Mayhew, E., Poste, G., Cowden, M., Tolson, N. and Maslow, D. (1974) Cellular binding of 3H-cytochalasin B. J. Cell Physiol. 84, 373-382.

398. Papahadjopoulos, D., Mayhew, E., Poste, G., Smith, S. and Vail, W.J. (1974) Incorporation of lipid vesicles by mammalian cells provides a potential method for modifying cell behavior. Nature 252, 163-166.

399. Reeve, P., Hewlett, G., Watkins, H., Alexander, D.J. and Poste, G. (1974) Virus-induced cell fusion enhanced by phytohaemagglutinin. Nature 249, 355-356.

400. Papahadjopoulos, D., Poste, G. and Mayhew, E. (1974) Cellular uptake of cyclic AMP captured within phospholipid vesicles and effect on cell growth behaviour. Biochim. Biophys. Acta 363, 404-418.

401. Poste, G., Alexander, D.J., Reeve, P. and Hewlett, G. (1974) Modification of Newcastle disease virus release and cytopathogenicity in cells treated with plant lectins. J. Gen. Virol. 23, 255-270.

402. Papahadjopoulos, D., Poste, G., Schaeffer, B.E. and Vail, W.J. (1974) Membrane fusion and molecular segregation in phospholipid vesicles. Biochim. Biophys. Acta 352, 10-28.

403. Poste, G. and Reeve, P. (1974) Increased mobility and redistribution of concanavalin A receptors on cells infected with Newcastle disease virus. Nature 247, 469-471.

404. Poste, G., Schaeffer, B., Reeve, P. and Alexander, D.J. (1974) Rescue of Simian virus 40 (SV40) from SV40- transformed cells by fusion with anucleate monkey cells and variation in the yield of virus rescued by fusion with replicating or nonreplicating monkey cells. Virology 50, 85-95.

405. Poste, G. and Allison, A.C. (1973) Membrane fusion. Biochim. Biophys. Acta 300, 421-465.

406. Poste, G. (1973) Anucleate mammalian cells: Applications in cell biology and virology. In: Methods in Cell Biology (ed. D.M. Prescott) Vol. 7, pp. 211-249. Academic Press, New York.

407. Alexander, D.J., Hewlett, G., Reeve, P. and Poste, G. (1973) Studies on the cytopathic effects of Newcastle disease virus: The cytopathogenicity of strain Herts 33 in five cell types. J. Gen. Virol. 21, 323-337.

408. Papahadjopoulos, D., Poste, G. and Schaeffer, B. (1973) Fusion of mammalian cells by unilamellar lipid vesicles: Influence of lipid surface charge, fluidity and cholesterol. Biochim. Biophys. Acta 323, 23-42.

409. Poste, G., Greenham, L.W., Mallucci, L., Reeve, P. and Alexander, D.J. (1973) The study of cellular "microexudates" by ellipsometry and their relationship to the cell coat. Exp. Cell Res. 78, 303-313.

410. Poste, G. (1973) The synthesis of surface coat materials in normal and transformed cells. Exp. Cell Res. 77, 264-270.

411. Lecatsas, G. and Poste, G. (1973) Mechanism of envelopment of herpesvirus by the nuclear envelope. Onderstepoort J. Vet. Res. 40, 71-72.

412. Alexander, D.J., Reeve, P. and Poste, G. (1973) Studies on the cytopathic effects of Newcastle disease virus: RNA synthesis in infected cells. J. Gen. Virol. 18, 369-373.

413. Poste, G. (1972) Electron microscope study of nuclear and nucleolar changes in cells infected with canine distemper virus. Arch. Ges. Virusforsch 37, 183-190.

414. Poste, G., Hawkins, D.F. and Thomlinson, J. (1972) Herpesvirus hominis infection of the female genital tract. Obstetrics and Gynecology 40, 871-890.

415. Poste, G., Lecatsas, G. and Apostolov, K. (1972) Electron microscope study of the morphogenesis of a new canine herpesvirus in dog kidney cell. Arch. Ges. Virusforsch 39, 317-329.

416. Poste, G. (1972) Characterization of a new canine herpes virus. Arch. Ges. Virusforsch 36, 147-157.

417. Poste, G., Reeve, P., Alexander, D.J. and Terry, G. (1972) Effect of plasma membrane lipid composition on cellular susceptibility to virus-induced cell fusion. J. Gen. Virol. 17, 133-136.

418. Poste, G., Reeve, P., Alexander, D.J. and Terry, G. (1972) Studies on the cytopathogenicity of Newcastle disease virus: Effect of lectins on virus infected cells. J. Gen. Virol. 17, 81-89.

419. Poste, G., Waterson, A.P., Terry, G. and Alexander, D. J. and Reeve, P. (1972) Cell fusion by Newcastle disease virus. J. Gen. Virol. 16, 95-97.

420. Poste, G. (1972) Changes in susceptibility of normal cells to agglutination by plant lectins following modification of cell coat material. Exp. Cell Res. 73, 319-328.

421. Poste, G. and Reeve, P. (1972) Enucleation of mammalian cells by cytochalasin B. II. Formation of hybrid cells and heterokaryons by fusion of anucleate and nucleated cells. Exp. Cell Res. 73, 287-294.

422. Poste, G. and Moss, C. (1972) The study of surface reactions in biological systems by ellipsometry. In: Progress in Surface Science

(ed. S.G. Davison) Vol. 2, pp. 139-232. Pergamon Press, Oxford.

423. K. Jeon) Vol. 33, pp. 157-252. Academic Press, New York.

424. Poste, G. (1972) Mechanisms of virus-induced cell fusion. In:International Review of Cytology (eds. J.F. Danielli and

425. Reeve, P., Poste, G., Alexander, D.J. and Pope, G. (1972) Studies on the cytopathic effects of Newcastle disease virus: Cell surface changes. J. Gen. Virol. 15, 219-225.

426. Apostolov, K. and Poste, G. (1972) Interaction of Sendai virus with human erythrocytes: A system for the study of membrane fusion. Microbios 6, 247-261.

427. Poste, G. (1972) Enucleation of mammalian cells by cytochalasin B. I. Characterization of anucleate cells. Exp. Cell Res. 73, 273-286.

428. Poste, G. and Reeve, P. (1972) Agglutination of normal cells by plant lectins following infection with nononcogenic viruses. Nature New Biology 237, 113-114.

429. Mallucci, L., Poste, G. and Wells, V. (1972) Synthesis of cell coat in normal and transformed cells. Nature New Biology 235, 222-223.

430. Poste, G. and Reeve, P. (1972) Inhibition of cell fusion by local anesthetics and tranquilizers. Exp. Cell Res. 72, 556-560.

431. Poste, G. and Reese, P. (1972) Inhibition of virus-induced cell fusion by local anaesthetics and phenothiazine tranquillizers. J. Gen. Virol. 16, 21-28. 21.

432. Poste, G. (1971) The growth and cytopathogenicity of virulent and attenuated strains of canine distemper virus in dog and ferret macrophages. J. Comp. Path. 81, 49-54.

433. Poste, G. and King, N. (1971) Isolation of a herpesvirus from the canine genital tract: Association with infertility, abortion and stillbirths. Veterinary Record 88, 229-233.

434. Reeve, P., Alexander, D.J., Pope, G. and Poste, G. (1971) Studies on the cytopathic effects of Newcastle disease virus. J. Gen. Virol. 11, 25-34.

435. Reeve, P. and Poste, G. (1971) Studies on the cytopathogenicity of Newcastle disease virus. I. Relation between virulence, polykaryocytosis and plaque size. J. Gen. Virol. 11, 17-24.

436. Poste, G. and Allison, A.C. (1971) The membrane fusion reaction: A theory. J. Theor. Biol. 32, 165-184.

437. Reeve, P. and Poste, G. (1971) Cell fusion by Newcastle disease virus in the absence of RNA synthesis. Nature New Biology 229, 1957-1958.

438. Poste, G. (1971) Sub-lethal autolysis: Modification of the cell periphery by lysosomal enzymes. Exp. Cell Res. 67, 11-16.

439. Poste, G. (1971) Tissue dissociation with proteolytic enzymes: Adsorption and activity of enzymes at the cell surface. Exp. Cell Res. 65, 359-367.

440. Poste, G. and Greenham, L. W. (1971) The measurement of cell surface glycoprotein coat materials by ellipsometry. 3. Synthesis of coat materials. Cytobios 3, 5-15.

441. Poste, G. and Reeve, P. (1971) Formation of hybrid cells and heterokaryons by fusion of enucleated and nucleated cells. Nature New Biology 229, 123-125.

442. Poste, G. (1971) Cell surface changes in virus-induced cell fusion. 2. Changes in cell coat thickness. Microbios 3, 55-61.

443. Poste, G. (1971) The role of lysosomes in virus-induced cell fusion. 2. Modification of the cell surface. Microbios 3, 105-112.

444. Greenham, L. W. and Poste, G. (1971) The role of lysosomes in virus-induced cell fusion. 1. Cytochemical studies. Microbios 3, 97-104.

445. Poste, G. (1970) Mixed-culture polykaryocytosis: A new form of cellular recognition behaviour. Life Sciences 9, 459-463.

446. Poste, G. and Greenham, L. W. (1970) The measurement of cell surface glycoprotein coat materials by ellipsometry. 2. Variation in coat thickness with cell type, tissue organization and culture conditions. Cytobios 2, 243-256.

447. Poste, G. (1970) The measurement of cell surface glycoprotein coat materials by ellipsometry. 1. The techniques. Cytobios 2, 233-241.

448. Poste, G. (1970) Cell surface changes in virus-induced cell fusion. 1. The importance of microvilli. Microbios 2, 227- 239.

449. Poste, G. (1970) Virus-induced polykaryocytosis and the mechanism of cell fusion. In: Advances in Virus Research (eds. F.B. Bang and K. Smith) Vol. 16, pp. 303-356, Academic Press, New York.

450. Poste, G. (1970) Increased growth of viruses in lymphocytes treated with heterologous antilymphocyte serum. Transplantation 10, 106-115.

Presentations: Visit casi.asu.edu/presentations/

2026

Poste, G. Trust in Biomedical Research, Public Health and Healthcare: A Core Value Under Siege. GETS Plenary Session (ASU Law, 5.21.2026)

Poste, G. Protecting Astronaut Health: A Grand Challenge for Prolonged Spaceflight and Inter-Planetary Exploration. ASU Discovery Seminar Series 2026 DH 107 (4.16.2026)

Poste, G. AI in Biomedical Research and Healthcare Delivery. Wise Guise Discussion Forum: Adobe Golf Course Phoenix, AZ (4.10.2026)

Poste, G. "The Strategic Architecture for Precision Health: Building Innovation at Scale in the Arizona Biomedical Ecosystem". AVEO PBC (2.9.2026)

Poste, G. Intelligent Healthcare: Biotechnology, AI and Precision Health. PUBLPOL/EMED 127/227: Winter 2026. Stanford University School of Medicine. Healthcare Leadership, January 21, 2026

Poste, G. Biosecurity in an Era of Disruptive Technological Change and Increased Geopolitical Tensions. BIOE 122, EMED 122/222, PUBLPOL 122/222 Stanford University School of Medicine. Biosecurity, January 21, 2026

2025

Poste, G. The Journey to Precision Health and Personalized Medicine. PMC 20th Annual Personalized Medicine Conference.Ritz-Carlton Laguna Niguel, Dana Point, CA (13 November 2025)

Poste, G. Intelligent Healthcare: Biotechnology, AI and Precision Health.PwC 2025 Innovation Exchange, The Cloister at Sea Island, GA (10.23.2025)

Poste, G. Diagnostics and AI: The Core Technology Drivers of Precision Health. ASU National Diagnostics Summit, ASU College of Health Solutions, Phoenix, AZ (15 October 2025)

ASU Digital Health Summit on Friday, February 14, 2025
Faculty Panel: George Poste, Matt Buman and Fang Yu, ASU College of Health Solutions

G Poste, Reconfiguring the Healthcare Ecosystem. The Future of Care. PwC Global Health Summit 2025. (5.13.2025)[Download PDF].

Poste, G. Protecting Astronaut Health: A Grand Challenge for Prolonged Spaceflight and Inter-Planetary Exploration. ASU Course L1-03: Living in Space: Know Before You Go! Spring Discovery Seminar (24 April 2025) [Download PDF].

Poste, G. The Strategic Landscape for the Evolution of Precision Health: Disruptive Changes in Biomedical Research, Public Health and Care Delivery. Stanford University School of Medicine, HEALTH CARE LEADERSHIP. Winter 2025 (1.22.2025) [Download PDF].

Poste, G. Biosecurity: Escalating Technological, Geopolitical and National Security Complexities. Stanford University School of Medicine, Winter 2025 (1.22.2025) [Download PDF].

2024

Poste, G. Biosecurity: Complexity, Complacency, Connectivity, Convergence & Commitment67th Annual Biosafety and Biosecurity ABSA International Conference, Phoenix (11.5.2024) [Download PDF].

Future Security Forum 2024: Global Security in the Next Decade (Day 1) [Download PDF]

Drs. Daniel Rothenberg and George Poste discussion titled: "Are We Prepared for the Next Pandemic?" (Mon 9/9/24, 4:45-5:10 PM.) [Download PDF].

Poste, G. AI and the Life Sciences: Evaluating Opportunities and Risks. GETs Conference. Sandra Day O'Connor College of Law, Arizona State University (5.16.2024) [Download PDF].

Poste, G. Protecting Astronaut Health: A Grand Challenge for Prolonged Spaceflight and Inter-Planetary Exploration. ASU Course LIA 194 ASU Spring Discovery Seminar (3.22.2024) [Download PDF].

Poste, G. The Strategic Landscape for the Evolution of Precision Health: Disruptive Changes in Biomedical Research, Public Health and Care Delivery. ASU Health Grand Rounds (1.29.2024) [Download PDF].

Poste, G. The Strategic Landscape for the Evolution of Precision Health: Disruptive Changes in Biomedical Research, Public Health and Care Delivery. PUBLPOL/EMED 127/227: Winter 2024HEALTH CARE LEADERSHIP. Stanford University School of Medicine (24 January 2024) [Download PDF].

Poste, G. Biosecurity: Complexity, Connectivity, Complacency & Commitment BioSecurity and Pandemic Resilience: Winter 2024, BIOE 122, EMED 122/222, PUBLPOL 122/222. Stanford University School of Medicine (January 24, 2024) [Download PDF].

2023

Poste, G. The Evolving Landscape for Precision Health and One Health:
New Opportunities in Human and Veterinary Medicine. Comparative Medicine Symposium 2023. ASU SkySong Innovation Center, Bldg 3; Synergy Rooms. Scottsdale, AZ (11.30.2023). [Download PDF].

Dev, S. Geographic Variation in Cardiac Amyloidosis in U.S. Veterans From 2012 to 2021 at the American Heart Association's annual Scientific Sessions 2023, Philadelphia, PA (November 10-13) [Download PDF].

Presentations continued: Visit casi.asu.edu/presentations/

Poste, G. The Evolving Landscape for Precision Oncology: Multidisciplinary Integration, Big Data, Artificial Intelligence and New Collaboration Networks Keynote University of Arizona Cancer Center Annual Scientific Retreat. Tucson, Arizona (2 November 2023) [Download PDF].

Poste, G. Pandemic Preparedness: Complexity, Complacency & Commitment. ASU Center on the Future of War Speaker Series. Zoom (Apr 27, 2023)
[Download PDF].

Poste, G. Protecting Astronaut Health: A Grand Challenge for Prolonged Spaceflight and Inter-Planetary Exploration. ASU Course LIA 194, Durham Hall (Apr 21, 2023)
[Download PDF].
Dev, S. Research Day: Data Blitz. UofA College of Medicine (Mar 29, 2023) [Download PDF].

Dev, S. Digital Twin for Precision Health. International Workshop on Digital Twin for Precision Health. Snowmass Village, CO (Feb 25, 2023) [Download PDF].

Poste, G. Global Biosecurity: Complexity, Complacency & Commitment. BIOE 122, EMED 122/222, PUBL POL 122/222: Global Biosecurity. Stanford University School of Medicine (Jan 23, 2023) [Download PDF].

Poste, G. Leadership Challenges in Biomedical Innovation in an Era of Disruptive Change, Escalating Complexity and Pervasive Uncertainty. PUBLPOL/EMED 127/227: Health Care Leadership Winter 2023 . Stanford University School of Medicine (Jan 23, 2023)
[Download PDF].

Poste, G. Building a Collaboration Network in Transthyretin Cardiac Amyloidosis: Challenges and Opportunities. Updates in Cardiac Amyloidosis 2023 Conference. Mayo-ASU Health Futures Center, Phoenix, Arizona (Jan 14, 2023) [Download PDF].

Dev, S. Epidemiology and Population Health Strategies for Cardiac Amyloidosis. Updates in Cardiac Amyloidosis 2023 Conference. Mayo-ASU Health Futures Center, Phoenix, Arizona (Jan 14, 2023) [Download PDF].

2022

Poste, G. Digital Technologies and Mental Health. ASU 8th Law & Neurosc. Conf.. Sandra Day O'Connor US Courthouse Phoenix (Dec 9, 2022) [Download PDF].

Poste, G. One Health and Global Biosecurity: Concept, Complexity and Commitment. SW One Health Symposium at the Coconino Center for the Arts. Flagstaff, Arizona (Nov 16, 2022)
[Download PDF].

Poste, G . The Strategic Landscape for the US Health Ecosystem and The Evolution of Precision Oncology: Challenges and Opportunities. Phoenix Children's Hospital (May 31, 2022) [Download PDF].

Poste, G. Biosecurity: A Multi-Dimensional Challenge of Escalating Complexity and Urgency (12 Jan 2022) Virtual Lecture. Stanford BioSecurity Class. [Download PDF].

Poste, G. Health Care Leadership (1.12.2022) Virtual Lecture. Healthcare Leadership Class (EMED 127/227) Stanford. [Download PDF].

2021

Poste, G. Characteristics, Accomplishments and Challenges of Existing Systems. Virtual Forum on Complex Food and Agricultural Systems: Engineering for Sustainability and Resilience. (Sep 9, 2021) [Download PDF].

Poste, G. Diagnostics Tests – The Critical Element in Pandemic Control. Stanford University School of Medicine-Virtual (Jan 27, 2021)
[Download PDF].

2020

Poste, G. The COVID-19 Diagnostics: The Achilles Heel of SARS-CoV-2 Pandemic Control Efforts. ASU Diagnostics Roundtable 2020. December 8, 2020 [Download PDF].

Poste, G. Planning for the Future (Nov. 23 – Dec. 4) Week 7. Overview of Biosecurity GSC 598 Fall 2020.
[Download PDF].

Presentations continued: Visit casi.asu.edu/presentations/

Poste, G. Pressing Threats II: New and Emerging Bioweapons (November 2020) Week 6. Overview of Biosecurity GSC 598 Fall 2020.
[Download PDF].

Poste, G. Pressing Threats I: New and Emerging Diseases and Patterns (November 2020) Week 5. Overview of Biosecurity GSC 598 Fall 2020 [Download PDF].

Poste, G. Biosecurity: Domestic and International Institutions (November 2020) Week 4. Overview of Biosecurity GSC 598 Fall 2020.
[Download PDF].

Poste, G. History of Biosecurity Threats: Pandemic and Plagues (October 2020) Week 2. Overview of BIosecurity GSC 598 Fall 2020
[Download PDF].

Poste, G. Biosecurity: Overview (October 2020) Video Lecture. Overview of Biosecurity GSC 598 Fall 2020
https://www.dropbox.com/s/34h4ewea47htmfc/GSC%20598%20Poste%20WK%201.mp4?dl=0.

Poste, G. Biosecurity: A Multi-Dimensional Challenge of Escalating Complexity and Urgency. Oncology Impact Partners:Virtual Infectious Disease and Immunology Conference (Jun 14, 2020)
[Download PDF].

Poste, G. The Biopharmaceutical Industry and the Healthcare Ecosystem: Challenges and Opportunities. ASU HSM 502 Spring 2020 McCord Hall 270 (Feb 6, 2020)
[Download PDF].

Poste, G. Precision Health and Digital Health: The Inter-Dependent Strategic Drivers of Innovation in Healthcare Delivery. EMED 227/127: HEALTH CARE LEADERSHIP. Stanford University School of Medicine, Li Ka Shing room 130 (Jan 22, 2020) [Download PDF].

Poste, G. Biosecurity: A Multi-Dimensional Challenge of Escalating Complexity and Urgency. Biosecurity and Bioterrorism Response Winter 2020. Stanford University School of Medicine, Li Ka Shing room 130 (Jan 22, 2020) [Download PDF].

2019

Poste, G. Development of Multi-Parameter Assays to Predict Therapeutic Response and Toxicity Risk in Immunotherapy. 26th International Molecular Med TRI-CON. San Francisco, CA (Mar 12, 2019) [Download PDF].

Poste, G. Challenges in Healthcare Innovation in An Era of Technology Acceleration, Convergence and New Value-Based Services. HEALTH CARE LEADERSHIP. Stanford University School of Medicine (Jan 23, 2019) [Download PDF].

Poste, G. Biosecurity: A Multi-Dimensional Challenge of Escalating Complexity and Urgency. Biosecurity and Bioterrorism Response. Stanford University School of Medicine (Jan 23, 2019) [Download PDF].